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Summary 
Antibiotic resistance has become a major threat to humankind, necessitating research and 
development of alternative antimicrobial compounds. Many bacteria, including lactic acid 
bacteria, produce small antimicrobial peptides, referred to as bacteriocins. These peptides are 
generally not toxic, are active at low concentrations and have a narrow spectrum of 
antimicrobial activity. However, they usually have low in vivo stability due to degradation by 
proteolytic enzymes. Drug delivery systems are thus required to transport bacteriocins to the 
site of infection. Probiotic bacteria are an attractive delivery system, since these bacteria 
normally colonise the gastrointestinal tract and produce bacteriocins.  
Numerous studies have been done on the probiotic Entiro™ which consists of Lactobacillus 
plantarum 423 and Enterococcus mundtii ST4SA. The bacteriocins produced by these strains, 
plantaricin 423 and bacST4SA, respectively, are active against a variety of pathogens and are 
potential alternatives to antibiotics. However, it is unknown whether these bacteriocins are able 
to migrate across the gastrointestinal epithelium and vascular endothelium in order to enter the 
bloodstream.  
The aim of this study was to evaluate the stability, cytotoxicity and permeability of plantaricin 
423 and bacST4SA in vitro and evaluate the potential use of these peptides as an alternative to 
antibiotics. The well-known lantibiotic, Nisin A, produced by Lactococcus lactis subsp lactis, 
was used as control and Listeria monocytogenes EGDe as target (sensitive) organism. 
Migration of the lantibiotic, nisin A and class IIa bacteriocins, plantaricin 423 and bacST4SA 
across simulated models of the vascular endothelial and gastrointestinal epithelial barriers was 
studied by growing human umbilical vein endothelial cells (HUVEC)- and human colonic 
adenocarcinoma (Caco-2) cells on transmigration inserts and adding fluorescently labelled 
nisin A, plantaricin 423 and bacST4SA to the inserts. All three peptides diffused across 
HUVECs and Caco2 cells. Only 21% nisin A, 11% plantaricin 423 and 12% bacST4SA 
remained attached to Caco-2 cells and only 6% nisin A and 3% bacST4SA attached to the 
HUVECs, and plantaricin 423 did not attach. The viability of both cell types remained 
unchanged when exposed to 50 µM nisin A, 50 µM plantaricin 423 and 50 µM bacST4SA, 
respectively. Furthermore, little extracellular lactate dehydrogenase (LDH) activity was 
recorded when cells were exposed to 100 µM of each peptide, suggesting that the peptides are 
not cytotoxic. The three peptides retained 60% of their antimicrobial activity when 25 µM of 
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each were exposed to 80% human plasma for 24 h. However, at higher concentrations (50 µM) 
68% of the original antimicrobial activity was recorded and at 100 µM the peptides retained 
79% of their activity. This is the first report of nisin A, plantaricin 423 and bacST4SA migrating 
across simulated gastrointestinal- and vascular barriers. In vivo studies are required to confirm 
these findings and determine the effect these peptides may have in the treatment of systemic 
infections.   
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Opsomming 
Antibiotika weerstandigheid het 'n groot bedreiging vir die mensdom geword en daarom is daar 
’n behoefte aan navorsing en ontwikkeling van alternatiewe antimikrobiese verbindings. Die 
meerderheid van bakterieë, insluitend melksuurbakterieë, produseer klein antimikrobiese 
peptiede, bekend as bakteriosiene. Hierdie peptiede is oor die algemeen nie toksies nie, is aktief 
teen lae konsentrasies en het 'n noue spektrum van antimikrobiese aktiwiteit. Hulle het egter 
gewoonlik ’n lae in vivo stabilteit as gevolg van afbraak deur proteolitiese ensieme. Effektiewe 
vervoersisteme vir geneesmiddels is dus nodig om bakteriosiene na die plek van infeksie te 
vervoer. Probiotiese bakterieë is ’n aantreklike voervoersisteem, aangesien hierdie bakterieë 
gewoonlik die spysverteringskanaal koloniseer en bakteriosiene produseer. 
Talle studies is gedoen op die probiotika, Entiro ™ wat bestaan uit Lactobacillus plantarum 
423 en Enterococcus mundtii ST4SA. Die bakteriosiene, plantarisien 423 en bakteriosien 
ST4SA (bakST4SA), wat deur hierdie stamme geproduseer word, is aktief teen ’n 
verskeidenheid patogene en is potensiële alternatiewe vir antibiotika. Dit is egter onbekend of 
hierdie bakteriosiene oor die spysverteringskanaal en vaskulêre endoteel kan migreer om die 
bloedstroom te bereik. 
Die doel van hierdie studie was om die stabiliteit, sitotoksisiteit en deurlaatbaarheid van 
plantarisien 423 en bakST4SA in vitro te evalueer om vas te stel of hierdie peptiede as 
alternatief vir antibiotika kan dien. Die bekende lantibiotikum, nisin A, geproduseer deur 
Lactococcus lactis subsp lactis, is gebruik as die kontrole baktieriosien en Listeria 
monocytogenes EGDe as teiken (sensitiewe) organisme. 
Migrasie van die lantibiotika, nisin A- en klas IIa-bakteriosiene, plantarisien 423 en bakST4SA 
oor gesimuleerde modelle van die vaskulêre endoteel en spysverterings versperrings was 
bestudeer deur endoteelselle vanaf menslike naelstring are (HUVECs) en kolonale 
adenokarsinoom (Caco-2) selle op transmigrasie houers te groei en  
fluoresserende nisin A, plantarisien 423 en bakST4SA by die houers in te voeg. Al drie peptiede 
het gediffundeer oor HUVECs en Caco2-selle. Slegs 21% nisin A, 11% plantarisien 423 en 
12% bakST4SA het gebonde gebly aan Caco-2 selle. Slegs 6% nisin A en 3% bakST4SA het 
gebonde gebly aan die HUVECs. Plantarisien 423 het nie geheg nie. Die lewensvatbaarheid 
van beide seltipes bly onveranderd wanneer dit blootgestel word aan 50 μM nisin A, 50 μM 
plantarisien 423 en 50 μM bakST4SA, onderskeidelik. Verder is baie min ekstrasellulêre 
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laktaat dehidrogenase (LDH)-aktiwiteit aangeteken wanneer selle aan 100 μM van elke peptied 
blootgestel is, wat daarop dui dat die peptiede nie sitotoksies is nie. Die drie peptiede behou 
60% van hul antimikrobiese aktiwiteit wanneer 25 μM van elk vir 24 uur aan 80% menslike 
plasma blootgestel is. Daar is egter by hoër konsentrasies (50 μM), 68% van die oorspronklike 
antimikrobiese aktiwiteit aangeteken en by 100 μM het die peptiede 79% van hul aktiwiteit 
behou. Dit is die eerste verslag wat raporteer op die vermoë van nisin A, plantarisien 423 en 
bakST4SA om oor gesimuleerde spysverteringskanale en vaskulêre grense te migreer. In vivo 
studies word vereis om hierdie bevindinge te bevestig en die effek te bepaal wat hierdie 
peptiede moontlik kan hê in die behandeling van sistemiese infeksies  
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
vi 
 
Bibliographical Sketch 
Leané Dreyer was born in Johannesburg, Gauteng on the 24th of January 1993. She matriculated 
in 2011 at Hermanus High School, Western Cape. She enrolled for a B.Sc. degree in Molecular 
Biology and Biotechnology (2012) at the University of Stellenbosch and obtained the degree 
in 2014. In 2015 she obtained her B.Sc. (Hons) in Microbiology at the University of 
Stellenbosch. She enrolled as a M.Sc. student in Microbiology at the University of Stellenbosch 
in 2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
vii 
 
Preface 
Each chapter of this thesis is introduced separately and has been written according to the 
instructions of the Journal of Applied and Environmental Microbiology.  
The literature review (Chapter 2) gives a broad overview of the antibiotic resistance crisis and 
bacteriocins as alternatives to antibiotics. The advantages and disadvantages of bacteriocins 
are discussed, with a focus on nisin A, plantaricin 423 and bacteriocin ST4SA. The importance 
of bacteriocins to maintain stability in in vivo environments and migrate across the 
gastrointestinal epithelium and vascular endothelium to be used as a therapeutic agent was 
researched and discussed. The literature review will be prepared for publishing.  
The manuscript “Migration of nisin A, plantaricin 423 and bacST4SA across gastrointestinal 
epithelial and vascular endothelial cells, as determined with simulated models” will be prepared 
for publishing and is presented in Chapter 3. 
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INTRODUCTION 
Antibiotic resistance has become a major threat to humankind, necessitating the discovery and 
development of alternative antimicrobial compounds (1). Many bacteria, including lactic acid 
bacteria (LAB), produce small antimicrobial peptides (AMPs), referred to as bacteriocins (2). 
These peptides are generally not toxic, are active at low concentrations and have a narrow 
spectrum of antimicrobial activity. However, they usually have low in vivo stability, especially 
in a complex environment such as the lumen, lamina propria or blood (3). Treatment of infected 
areas is thus only possible by using specifically designed drug delivery systems. Probiotic 
bacteria are an attractive delivery system, since these bacteria normally colonise the 
gastrointestinal tract (GIT) (4, 5). Bacteriocins produced in the GIT might diffuse through the 
gut-blood barrier (GBB) and reach infected areas.  
This study focuses on two strains, Lactobacillus plantarum 423 and Enterococcus mundtii 
ST4SA, present in the probiotic Entiro™. Both strains adhere to the mucus and epithelial cells 
in the GIT, thereby preventing the adhesion of pathogens to the same receptor sites (6). The 
bacteriocins produced by these strains, plantaricin 423 and bacteriocin ST4SA (bacST4SA), 
belong to class IIa and form pores in the cell membrane of target cells (7). Both bacteriocins 
are small (3935 Da and 4288 Da, respectively) and they have a good chance of migrating 
through the GBB. They are both active against various pathogens such as Staphylococcus 
aureus, Clostridium sporogenes and Listeria monocytogenes. Listeria monocytogenes is an 
opportunistic pathogen that causes listeriosis (food poisoning) and is considered a large risk to 
immune-compromised (AIDS) patients (8).   
The development of a new antimicrobial compound takes many years and requires several in 
vitro and in vivo studies (9). The first phase of drug development usually involves experiments 
on human cell lines. Apart from using fewer experimental animals, studies on tissue culture are 
less expensive and results are obtained in a shorter period. Valuable information is obtained 
regarding the cytotoxicity, efficacy, permeability and transport of the tested compound (10). 
Results obtained from in vitro tissue culture studies, provide valuable insight to knowledge 
gained from in vivo and other in vitro studies. 
The aim of this study was to evaluate the stability, cytotoxicity and permeability of plantaricin 
423 and bacST4SA in vitro and evaluate the potential use of these peptides as an alternative to 
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antibiotics. The well-known lantibiotic, Nisin A, produced by Lactococcus lactis subsp lactis, 
was used as control and Listeria monocytogenes EGDe as target (sensitive) organism. 
The objectives of this study were: 
• to isolate and purify plantaricin 423 and bacST4SA from cultures of the wild-type 
strains; 
• to determine the minimum inhibitory (MIC) concentration of each bacteriocin by using 
L. monocytogenes EGDe as target; 
• to determine the stability of the bacteriocins in the presence of human blood plasma; 
and 
• to label the peptides with a fluorescent marker and determine their ability to diffuse 
across endothelial- and epithelial cells, using simulated models of the gastrointestinal 
epithelial and vascular endothelial barriers. 
REFERENCES 
1.  Centers for Disease Control and Prevention (CDC). 2013. Antibiotic resistance threats 
in the United States. 
2.  Cotter PD, Ross RP, Hill C. 2013. Bacteriocins - a viable alternative to antibiotics? 
Nature reviews Microbiology 11:95–105. 
3.  Gillor O, Etzion A, Riley MA. 2008. The dual role of bacteriocins as anti- and probiotics. 
Applied Microbiology and Biotechnology 81:591–606. 
4.  Marteau P, Shanahan F. 2003. Basic aspects and pharmacology of probiotics: an 
overview of pharmacokinetics, mechanisms of action and side-effects. Best Practice & 
Research Clinical Gastroenterology 17:725–740. 
5.  Bajaj BK, Claes IJJ, Lebeer S. 2015. Functional mechanisms of probiotics. Journal of 
Microbiology, Biotechnology and Food Sciences 4:321–327. 
6.  Van Zyl WF. 2015. Fluorescence and bioluminescence imaging of the intestinal 
colonization of Enterococcus mundtii ST4SA and Lactobacillus plantarum 423 in mice 
infected with Listeria monocytogenes EGDe. Stellenbosch University. 
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7.  Dicks LMT, Ten Doeschate K. 2010. Enterococcus mundtii ST4SA and Lactobacillus 
plantarum 423 Alleviated Symptoms of Salmonella Infection, as Determined in Wistar 
Rats Challenged with Salmonella enterica Serovar Typhimurium. Current Microbiology 
61:184–189. 
8.  Vázquez-Boland J, Kuhn M, Berche P, Chakraborty T, Domínguez-Bernal G, Goebel 
W, González-Zorn B, Wehland J, Kreft J. 2001. Listeria Pathogenesis and Molecular 
Virulence Determinants. Clinical Microbiology Reviews 14:584–640. 
9.  Andrade EL, Bento AF, Cavalli J, Oliveira SK, Freitas CS, Marcon R, Schwanke RC, 
Siqueira JM, Calixto JB. 2016. Non-clinical studies required for new drug development 
– Part I : early in silico and in vitro studies , new target discovery and validation , proof 
of principles and robustness of animal studies. Journal of medical and biological 
research 49:1–9. 
10.  Amelian A, Wasilewska K, Meqias D, Winnicka K. 2017. Application of standard cell 
cultures and 3D in vitro tissue models as an effective tool in drug design and 
development. Pharmacological Reports 69:861–870. 
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LITERATURE REVIEW 
Antibiotic resistance 
The discovery of penicillin in 1928 by Alexander Fleming was a life-changing event in the 
history of medicine (1). Before the discovery of penicillin, there was no effective treatment for 
infections such as rheumatic fever, gonorrhoea or pneumonia. Hospitals were filled with 
patients suffering from sepsis contracted from simple cuts or scratches. The likelihood of dying 
prematurely due to infectious diseases in the early 19th century was as high as 40% (2). 
Penicillin and many other antibiotics discovered in later years were seen as powerful medicines 
and have saved millions of lives from life-threatening infectious diseases. At the time, scientists 
assumed that infectious diseases would no longer be a threat to society. 
Unfortunately, shortly after World War II the advances of the prior decade were threatened by 
bacteria that became resistant to penicillin (3). The hopes of many people were shattered as 
they came to the realization that this “miracle drug” was no longer effective. In response to the 
crisis, new beta-lactam antibiotics were discovered and developed. For a short while the 
discovery of novel antibiotics restored medical practitioners’ confidence in antibiotics. 
However, the first methicillin-resistant strain of Staphylococcus aureus (MRSA) was identified 
the same decade. Most of the antibiotics currently in use were developed between the 1960s 
and 1980s. However, within a few months of use, bacteria resistant to each of the newly 
developed antibiotics were isolated. Resistance to antibiotics reached disastrous levels, with 
some strains being resistant to all classes of antibiotics. Some strains of Acinetobacter 
baumannii, are resistant to carbapenem antibiotics, considered to be the “last resort antibiotics” 
(4). Several strains of Pseudomonas aeruginosa, Enterococcus faecium, Helicobacter pylori 
and Streptococcus pneumoniae are amongst the most resistant to antibiotics. In September 
2016, a woman from Nevada died after becoming infected with an antibiotic-resistant strain of 
Klebsiella pneumoniae (5). She contracted bone infection after breaking her leg and died from 
septic shock. The strain was resistant to all 26 of the available antibiotics in the United States, 
including, colistin. Cases such as this will continue to occur and increase as more antibiotic 
resistant bacteria emerge.  
Antibiotics are amongst the most commonly prescribed drugs (6). As many as 50% of the 
prescribed antibiotics are either not required, or are not effective in treating the infection. 
Despite this, doctors continue to prescribe antibiotics. In the USA, more than five prescriptions 
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are written each year for every six patients (7). The unnecessary prescription of antibiotics has 
led to the selection of bacteria resistant to several antibiotics (8). Genes encoding resistance to 
antibiotics is shared amongst pathogens, often across species borders, through horizonal gene 
transfer. To add to the problem, only few new antibiotics have been discovered over the last 
decade (9). If antibiotic resistance continues to spread, our integrative, highly technological 
world may find itself back in the dark ages of medicine. The World Health Organisation 
(WHO) has already declared antibiotic resistance a global crisis, worse than the AIDS 
epidemic. Antimicrobial resistance to tuberculosis, hospital acquired infections and common 
bacterial diseases is increasing mortality rates drastically (10). At least two million individuals 
in the United States (US) contract serious antibiotic-resistant bacterial infections each year 
(11). Approximately 23 000 people die each year due to infections caused by antibiotic-
resistant bacteria.  
Initial research showed that a continued increase in antibiotic resistance may lead to the death 
of 10 million people by 2050. Should this happen, the Gross Domestic Product (GDP) may 
decrease by as much as 3.5%, costing the world up to 100 trillion USD (11). Countries with 
high incidences of HIV and TB will, without doubt, suffer the most as resistance to antibiotics 
increase (11). South Africa may thus be heading for a major disaster. 
Despite the frightening statistics set above, it does not capture the full picture of what a world 
without antimicrobials would be like (11). Prophylactic antibiotics are given to most patients 
after surgery to decrease the risk of bacterial infections. If antibiotics become useless, surgery 
would become far more dangerous. Many simple surgical procedures might be too menacing 
to attempt. Chemotherapy often suppresses patients’ immune systems. Therefore, without 
antibiotics it would be impossible to prevent infection during cancer treatments. The same 
applies to AIDS and TB patients who also have weakened immune systems. An increase in 
antimicrobial resistance will also have an alarming effect on the safety of childbirth, resulting 
in high numbers of maternal and infant mortality. From a more direct perspective, less people 
would be willing to travel and trade. This will have a severe impact on all economies, 
particularly countries that depend on foreign investment, global trade and tourism. 
Resistance to antibiotics is not just a health issue, but also a major economic problem (12). 
Ultimately, the cost of dealing with antimicrobial resistance is much less than dealing with 
potential consequences. This crisis requires immediate attention and although the next step is 
uncertain, it is clear that there is an urgent need for research and development of new target-
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specific antibacterial compounds active against a broad range of pathogens. Several 
alternatives to antibiotics have been investigated. These include plant-derived metabolites, 
bacteriophages, RNA therapeutics, probiotics and antimicrobial peptides (AMPs) (9). 
Antimicrobial peptides 
Antimicrobial peptides (AMPs) may be a viable alternative to antibiotics (13). The first AMP 
to be fully described was Gramicidin, which was discovered in 1939 by the French 
microbiologist, René Dubos (8). Gramicidin, produced by Bacillus brevis, is active against 
Gram-positive bacteria.  Since this discovery, a number of AMPs produced by insects, plants, 
humans and bacteria, have been described (10). Most AMPs are positively charged, smaller 
than 10 kDa and usually consist of hydrophobic and hydrophilic residues. Therefore, AMPs 
are able to dissolve in aqueous environments and enter lipid membranes (13).  
The structure and positive charge of AMPs play a significant role in their mode of action (13). 
The positive charge allows AMPs to be attracted by negatively charged components, such as 
lipids in membranes of bacteria, fungi, viruses and protozoa.  The amphipathic structure of 
AMPs permits penetration through membranes. Antimicrobial peptides are favourable 
candidates for novel therapeutic agents, since they are highly diverse in structure, extremely 
specific, widely distributed in nature and have low toxicity towards eukaryotes (8, 10). 
Moreover, AMPs are mainly active against specific bacterial groups, making them less harmful 
to microbiota in the human gastrointestinal tract (GIT). These peptides can be administered 
alone or in combination with other antimicrobial agents to treat infections (10). They also 
neutralize endotoxins produced by pathogens, or act as immune-stimulatory agents (14). 
Bacteriocins, a subgroup of peptides, may be used as alternatives to antibiotics.  
Bacteriocins 
Bacteriocins as alternative to antibiotics 
Bacteriocins are ribosomally synthesized, post-translationally modified antimicrobial peptides 
that have the ability to inhibit the growth of closely related bacterial species (12). Virtually all 
bacterial species can produce at least one bacteriocin. Consequently, there is a vast diversity in 
the structure and mode of action of bacteriocins. The majority of bacteriocins that have been 
identified and characterized are produced by Gram-positive bacteria, particularly lactic acid 
bacteria (LAB)  (15). Lactic acid bacteria have GRAS (generally recognized as safe) status that 
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renders them attractive bacteriocin producers. Most bacteriocins produced by LAB are smaller 
than 10 kDa, heat stable and act by permeabilizing the cell membrane of the target bacterium 
(16).  
Bacteriocins produced by Gram-positive bacteria are divided into class I (modified 
bacteriocins) and class II (non-modified bacteriocins) (17, 18). Subclass Ia represents 
lantibiotics, defined as membrane-active peptides with thioether-containing amino acids such 
as, lanthionine (Lan) and β-methyllanthionine (MeLan). These amino acid residues are formed 
by a two-step post-translational process, catalysed by the enzymes, cyclase, dehydratase and 
synthetase. The Lan and MeLan residues form a crosslink that results in the formation of cyclic 
structures. Certain lantibiotics are composed of two peptides and may contain other post-
translationally modified amino acids that may affect the structure and properties. Subclass Ib 
bacteriocins consist of labyrinthopeptins (18). Labyrinthopeptins contain labionins, i.e. 
modified carbacyclic amino acid residues that form cyclic structures. Subclass Ic bacteriocins 
are known as sactibiotics. Sactibiotics are characterized by sulphur and carbon molecules 
forming cross links. Class II bacteriocins are defined as non-lantibiotic, membrane active, heat-
stable peptides, divided into three subclasses (18). Subclass IIa contains the anti-listeria, 
pediocin-like peptides, subclass IIb consist of two peptides and subclass IIc the thiol-activated 
peptides. Class III bacteriocins are heat-labile and commonly display enzymatic activity. Class 
IV are complex proteins. 
Bacteriocins are often membrane permeabilizing, positively charged and hydrophobic or 
amphiphilic, but usually display different modes of action (15). A single bacteriocin can have 
more than one target site, depending on the primary structure.  Bacteriocins function primarily 
at the cell envelope or within the cell by affecting the expression of genes and the production 
of proteins (9). Many lantibiotics, such as nisin, act by binding to lipid II during which they 
either inhibit peptidoglycan synthesis or form pores in the cell membrane (15). Bacteriocins in 
class IIa bind to susceptible cells by using components of the mannose phosphotransferase 
system as receptors and form pores in the cell membrane. Bacteriocins can also kill target cells 
by inhibiting DNA-, RNA- or protein-synthesis.  
Bacteriocins have many beneficial properties which make them viable alternatives to 
antibiotics (9). These include their potency and high specific activity against pathogens. 
Lantibiotics and thiopeptides are generally more active against Gram-positive strains. 
Lantibiotics such as nisin, gallidermin and mutacin are active against Streptococcus 
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pneumoniae, vancomycin-resistant enterococci (VRE), Clostridium difficile, methicillin-
resistant Staphylococcus aureus (MRSA) and several mycobacteria. Another benefit of 
bacteriocins is their low oral toxicity towards humans (9). Several studies report the lack of 
toxicity of bacteriocins. Although cytotoxicity has been reported in certain studies, it is rare. 
Broad- and narrow spectrum bacteriocins have been described. Many bacteriocins display 
broad-spectrum antimicrobial activity. This is an attractive trait to target infection of unknown 
cause. However, broad-spectrum bacteriocins can kill mutualistic microbiota. Therefore, 
bacteriocins with narrow-spectrum antimicrobial activity might be more beneficial under 
certain circumstances. 
This review addresses the lantibiotic nisin A, and the class IIa bacteriocins, plantaricin 423 and 
bacteriocin ST4SA. Properties of these bacteriocins render them possible alternatives to 
antibiotics. 
Nisin A 
Nisin A, produced by Lactococcus lactis subsp. lactis, is composed of 34 amino acids and 
contains the post-translationally modified amino acid residues, α,β-didehydroalanine,             
α,β-didehydrobutyrine, m-lanthionine and (2S,3S,6R)-3-methyl-lanthionine (28, 29). This 
lantibiotic is active against a variety of Gram-positive bacteria, including Listeria, 
Staphylococcus, Bacillus and Clostridium spp. (10). The peptide binds to lipid II in the bacterial 
cell wall and prevents cell wall biosynthesis. Another mode of action is pore formation in the 
cell membrane. Nisin binds to the pyrophosphate structures of lipid II using its A and B 
lanthionine rings on the (N)-terminal (Figure 1). By bending at the flexible region between the 
C and D rings, nisin inserts the carboxy (C)- terminal end into the phospholipid bilayer of the 
cell membrane. This causes the formation of aqueous transmembrane pores, leading to 
depolarization of the bacterial cytoplasmic membrane and the efflux of nucleotides, amino 
acids, ions and other cytoplasmic metabolites, resulting in cell death (20). 
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Figure 1 Binding of nisin to lipid II. Nisin acts by (a) inhibiting cell wall synthesis or by (b) 
forming pores in the cell membrane. Adapted from (20). 
Nisin has GRAS status and has therefore been used as a food preservative for many years (21). 
This lantibiotic gained significant recognition due to its high potency, broad spectrum of 
activity, low cytotoxicity and low likelihood of sensitive bacteria developing resistance. 
Numerous studies described the efficacy of nisin as an antimicrobial drug and it can, therefore, 
be regarded a viable alternative to antibiotics.  
Plantaricin 423 
Plantaricin 423 is a class IIa bacteriocin produced by Lactobacillus plantarum 423, isolated 
from sorghum beer (22). Lactobacillus plantarum 423 is commonly found in fermented foods 
and occurs naturally in the human GIT (23). This strain has many probiotic properties and is 
included in the probiotic, Entiro™, in combination with Enterococcus mundtii ST4SA. 
Extensive in vitro and in vivo studies have shown that L. plantarum 423 withstands harsh 
conditions of the GIT and attaches to the small intestine using specific adhesion molecules 
(23). This prevents gastrointestinal pathogens such as Listeria monocytogenes from attaching 
to this area of the GIT (24, 25). In a study done by Van Zyl et al. (23) in vivo bioluminescence 
was used to prove that colonization of mice with L. plantarum 423 and E. mundtii ST4SA 
prevented systemic L. monocytogenes EGDe infection. Thus, probiotic lactic acid bacteria may 
offer an alternative to conventional antibiotics in the treatment of Listeria infections. However, 
in a study done by Botes et al. (24) adhesion of L. monocytogenes ScottA to Caco-2 cells was 
not prevented by L. plantarum 423 and E. mundtii ST4SA. Instead the cell-free supernatants 
a) Inhibition of cell wall synthesis b) Pore formation 
Nisin 
Lipid II 
Cell membrane 
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of these strains, containing the antimicrobial peptides, plantaricin 423 and bacteriocin ST4SA 
(bacST4SA), prevented the invasion of L. monocytogenes ScottA into Caco-2 cells. 
Plantaricin 423 is active against a variety of Gram-positive bacteria, including many 
opportunistic pathogens such as Listeria monocytogenes, Enterococcus faecalis, Clostridium 
sporogenes and Streptococcus thermophilus (26). The peptide forms pores in the cytoplasmic 
membrane, leading to dissipation of the proton motive force and cell death. Plantaricin 423 
binds to target cell membranes by means of electrostatic interactions between its positively 
charged amino acids and negatively charged phospholipids in the bacterial membrane      
(Figure 2). Although activity is inhibited by proteinase K, pepsin, papain, α-chymotrypsin and 
trypsin, the peptide remains active after 30 min at 100℃. Plantaricin 423 is small (3935 Da), 
which increases the likelihood of the peptide diffusing across the gut-epithelial barrier to 
prevent gastrointestinal infections. 
Bacteriocin ST4SA 
Bacteriocin ST4SA (bacST4SA), belongs to class IIa and it is produced by Enterococcus 
mundtii ST4SA (27). Strain ST4SA was isolated from soybeans and is regarded as safe. No 
detrimental effects were recorded when tested on mice (28). No abnormalities in blood profiles 
or organ functions were recorded during a safety study on humans (classified information). 
Strain ST4SA prefers a less acidic environment and anaerobic conditions, and adheres to the 
lower part of the gastrointestinal tract. Enterococcus mundtii ST4SA also has the ability to 
adhere to Caco-2 cells under conditions simulating those of the GIT, as reported by                 
Botes et al. (24). The antimicrobial peptide produced is 4288 Da in size and it is active against 
Gram-positive pathogens such as Staphylococcus aureus, Enterococcus faecalis and 
Streptococcus pneumoniae (27). Bacteriocin ST4SA is also active against Gram-negative 
bacteria such as Klebsiella pneumoniae and Pseudomonas aeruginosa. This is an unusual 
phenomenon, since most bacteriocins are only active against Gram-positive species (29). 
Similarly to plantaricin 423, bacST4SA acts by dissipation of the proton motive force (Figure 
2) and may play an important role in the competitive exclusion of pathogens in the gastro-
intestinal tract (30).  
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Figure 2 Illustration of the mode of action of class IIa bacteriocins such as plantaricin 423 and 
bacST4SA. Class IIa bacteriocins form ion-selective pores in the cell membrane by binding to 
a pore forming receptor such as the Mannose phosphotransferase system (Man-PTS) resulting 
in dissipation of the proton motive force and depletion of intracellular ATP. Adapted from (31). 
Disadvantages of bacteriocins and possible solutions 
Although bacteriocins have many properties which suggest that they are viable alternatives to 
antibiotics, a number of limitations need to be addressed (12). It should be noted that the 
emergence of resistant bacteria is a possibility (32). In addition, bacteriocin toxicity has been 
reported towards eukaryotes. Furthermore, the production, stability, administration and 
delivery of bacteriocins are also major obstacles that should be kept in mind when using 
bacteriocins for clinical use. These limitations require extensive research.  
Toxicity 
Data on the effect of bacteriocins on the host in terms of toxicity and immune response are 
limited (33). However, from the limited data available, minimal toxic effects against the host 
have been reported. One of the foremost examples in the lantibiotic, nisin A, which has been 
used as a food preservative for many years, without having any detrimental effects to 
consumers (34). An in vivo safety evaluation was done by Sahoo et al. (35) to determine the 
toxicity of bacteriocin TSU4 and ensure its safety in industrial applications. Bacteriocin TSU4 
was administered to Male BALB/c mice for toxicity tests. No mortality or infections were 
observed during the experimental period. Additionally, there was no major increase in antibody 
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Direct membrane 
permeabilization 
Class IIa bacteriocin 
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count during immunogenicity tests. However, in certain cases toxicity has been reported. In a 
study done by Gupta et al. (36) the toxic effect of a mixture of AMPs isolated from L. plantarum 
LR/14 was evaluated on Drosophila melanogaster. Significant toxicity and a delay in the life 
cycle of the fly were observed when it was exposed to 10 mg/ml of the peptide mixture. Since 
limited data is available on the toxicity of bacteriocins, more research is required to determine 
the dosage and timing of bacteriocin administration. 
Previous studies have shown that some eukaryotic cells are more sensitive towards certain 
bacteriocins than others. Vaucher et al. (37) investigated the in vitro cytotoxicity of the 
antimicrobial peptide, P40 (produced by Bacillus licheniformis P40) against VERO cells. P40 
had much higher hemolytic activity compared to nisin. Testing in a variety of models and 
detailed pharmacokinetic studies are therefore required before bacteriocins can be administered 
to humans.  The determination of the cytotoxicity of antimicrobial peptides is a crucial step to 
permit their safe use.  
Resistance 
Resistance to bacteriocins has occurred. It is crucial to evaluate the risk of resistance 
development once a new drug has been described and proven to be effective and safe (9). 
Additionally, it is important to evaluate the frequency at which an organism can develop 
resistance to a given bacteriocin (38). The mechanisms involved in bacteriocin resistance can 
be divided into a) acquired resistance and b) innate resistance (38, 39). 
Innate resistance may result from different mechanisms such as immunity mimicry, bacteriocin 
degradation, bacterial cell-envelope changes and resistance associated with growth conditions 
(38). During immunity mimicry, non-bacteriocin-producing strains carry genes that are 
homologous to bacteriocin immunity systems. Expression of these genes confers protection 
against the associated bacteriocin. Certain bacteria can also produce proteases that degrade 
bacteriocins. Some Bacillus spp. such as Bacillus cereus and Paenibacillus polymyxa produce 
nisinase during sporulation, which degrades nisin (40). Additionally, mutations in genes that 
code for proteins required for the structure of the cell envelope can lead to changes in the charge 
and structure of the cell envelope and this can also result in resistance development towards 
certain bacteriocins. Another mechanism that can lead to innate resistance is associated with 
the growth conditions of bacteria. In a study done by Jydegaard et al. (41), bacteriocin 
inactivation by L. monocytogenes 412 was studied with comparison to its growth phase. Cells 
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in their stationary phase of growth exhibited higher resistance rates to nisin and pediocin than 
cells in their exponential phase. This can be attributed to the fact that stationary phase bacteria 
are more resistant or adaptable to stress conditions such as high or low osmotic concentrations, 
acidic conditions or heat shock (42). Moreover, during the stationary phase no cell wall 
synthesis occurs, resulting in the absence of lipid II. Thus, bacteriocins that act by binding to 
lipid II, such as nisin, cannot bind to the cell wall. 
Unlike innate resistance, the properties associated with acquired resistance are only found in 
certain strains of each bacterial species (38). The mechanisms responsible for resistance vary 
greatly amongst different strains and species. Acquired resistance results from gene mutations 
or horizontal gene transfer via transformation, conjugation or transduction (38). These 
mutations or gene alterations result in changes in the cell wall, cell membrane, receptors or 
transport systems, which consequently leads to resistance. 
To improve the effectiveness of individual bacteriocins and to prevent the emergence of 
resistance, bacteriocins could be used in combination with other antimicrobials or membrane- 
active substances (12, 38). The use of bacteriocins with different modes of action may also 
reduce the dosage of bacteriocins. Moreover, since resistance from one bacteriocin may extend 
to another, especially of the same class, it would be preferable to use bacteriocins of different 
classes or subclasses. Thus, preliminary studies should be done to determine the most effective 
combinations of bacteriocins by examining the possibility of cross-resistance before integrating 
them. Additionally, bioengineering bacteriocins may also lead to a diminished rate of resistance 
development and also contribute towards better production (18).  
Production 
The purification of bacteriocins from cell culture is a time-consuming and expensive process 
(43). Heterologous expression is a viable alternative for the mass production of bacteriocins 
and can deliver large quantities of the desired bacteriocin (9). Unfortunately, in most cases the 
peptides eventually kill the producing cell (44). However, an advanced understanding of the 
production machinery of bacteriocins has shown that it may be possible to overcome these 
problems (45). The design of an efficient expression system depends on various aspects such 
as cell growth, location of the final recombinant peptide, the level of expression and choice of 
genes, plasmids and regulatory factors (46).  
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Echerichia coli is used as the primary prokaryotic host for cloning and expression since its 
genome has been extensively characterized (46). Additionally, many tools are available for its 
manipulation. However, this organism is not suitable for every application due to potential 
toxicity of the recombinant proteins, and their stability, translation and structural 
characteristics. Moreover, E. coli may lack the required secretion proteins in its cell wall since 
it is a Gram-negative organism. Other bacteria may offer advantages as host for heterologous 
expression. Certain LAB species show tremendous advances in expression and gene 
stabilization. In a study done by Chikindas et al. (47), production and secretion of             
pediocin PA-1 was achieved in Pediococcus pentosaceus PPE1.2 that had been transformed 
with a plasmid containing the ped operon under control of the lactococcal promoter P32. The 
amount of pediocin produced was 4-fold higher than that of the natural producer. 
Additionally, heterologous production of bacteriocins is further advanced by adding signalling 
peptides that are recognised by secretory pathways. McCornick et al. (48) transformed 
Carnobacterium divergens LV13 with pJKM14, a plasmid containing the carnobacteriocin B2 
immunity gene and a fusion between the sequence encoding the signal peptide of divergicin A 
and mature carnobacteriocin B2. The transformation resulted in coproduction of divergicin A 
and carnobacteriocin B2. In another study heterologous production of enterocin B (produced 
by certain strains of Enterococcus faecium) in C. piscicola LV17A was achieved by 
transforming the host with a plasmid containing enterocin B structural (entB) and immunity 
(eniB) genes (49). Many extensively studied systems may serve as useful models to produce 
LAB bacteriocins. 
Administration, stability and delivery 
Conventional antibiotics are administered orally, subcutaneously, intravenously or 
intramuscularly (12). Parenteral invasive administration is required for bacteriocins since they 
have a peptidic nature (50). Oral administration is only suitable for local applications since 
bacteriocins are susceptible to proteases, heat and other stresses. Bacteriocins are also known 
to have a very short plasma half-life.  
Once bacteriocins have been administered, they have to be delivered to the site of infection, 
which has also been a major challenge (12). The physiochemical properties of bacteriocins are 
an obstacle when they are applied in a chemically complex environment. Since they are 
positively charged and hydrophobic or amphiphilic, they might not reach the targets efficiently 
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because of unspecific adherence to negatively charged or lipophilic surfaces or molecules. 
Many bacteriocins bind strongly to blood cells and plasma proteins, lowering the availability 
of the peptide (51). Additionally, the interaction of the peptides with blood components can 
change their effectiveness against a certain bacterial strain. Peptides that are administered 
orally may not be easily absorbed if they are larger than 3 kDa in size and smaller peptides may 
be denatured by digestive proteases (12). To solve this problem, techniques are required with 
witch to efficiently deliver the peptides to the bacterial targets.  
A detailed understanding of their mechanisms of action and peptide engineering may be the 
solutions to the issues related to the administration, stability and delivery of bacteriocins. 
Another viable alternative would be to use a protective vector that transports the peptide to the 
specific site. Ugurlu et al. (52) used specialized tablets to deliver nisin to specific parts of the 
gut. Nanoparticle systems, hydrogel beads, microspheres and matrix tablets are other examples 
of natural polymer-based colon drug delivery systems (53). All the available approaches have 
limitations and advantages and require further research. Some bacteriocins benefit from the 
fact that, in addition to being administered by standard methods, they have the potential to be 
produced at the site of infection by probiotic bacteria (54). Probiotics protect the bacteriocins 
against acids in the stomach as well as proteases and other factors present in the GIT and can 
deliver them to the target site by serving as a vector system. Probiotics are a possible solution 
for most of the delivery based problems mentioned above, since antimicrobial activity is 
thought to be an important means for probiotics to competitively exclude or inhibit invading 
bacteria and can therefore be used in the treatment of gastrointestinal infections. 
Intestinal Microbiota 
The gastrointestinal tract is the most complex ecosystem in the human body, containing more 
than 1014 microorganisms (55). These microbes play a vital role in establishing the intestinal 
immune system and improve nutrient and energy uptake. The majority of intestinal bacteria 
that have been isolated are mainly from the phyla of Actinobacteria, Firmicutes, Bacteroidetes 
and Proteobacteria (55). However, these isolated bacteria represent less than 10% of the total 
intestinal microbiota. Furthermore, the intestinal microbial composition of everyone is unique. 
It is estimated that approximately 1000 microbial species reside in the human intestinal tract 
with only about 15% that are shared among individuals (56).  Many factors contribute towards 
the composition of an individual’s microbiota, these include route of birth, feeding pattern 
during childhood, antibiotic treatment, diet, disease, medication, consumption of alcohol, etc. 
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Studies have proven that certain metabolites that are secreted by intestinal bacteria may cause 
diseases and that alterations of intestinal microbiota are linked to certain infections, 
inflammatory bowel diseases (IBD), obesity, diabetes, cardiovascular disease, mental disease, 
auto-immune disease, cancer, etc (55, 57).  
The Gut-Blood barrier 
The GBB is an intricate system, containing multiple layers as illustrated in Figure 3 (57). The 
barrier plays an important role in maintaining homeostasis between the blood stream and 
gastrointestinal tract. It regulates the absorption of water, electrolytes and nutrients from the 
gut lumen, into the bloodstream (58). The intestinal barrier also serves as a protective barrier 
by preventing pathogenic microorganisms and luminal toxins from entering the blood stream 
(59). It contains a mucus layer, an epithelial cell lining and a vascular endothelium layer. 
 
 
 
 
 
 
 
Figure 3 The GBB consists of a mucus layer, a monolayer of epithelial cells and a monolayer 
of endothelial cells that line blood vessels. This barrier protects the host by preventing passage 
of harmful compounds or pathogens from the gut lumen to the bloodstream. Adapted from 
(57). 
Mucus layer 
The mucus layer (Figure 3) forms a protective coat on the epithelium (59). This layer protects 
villi from physical friction caused by luminal content, chemical toxins and adhesion of bacteria. 
It also forms an important diffusion barrier, restricting the movement of certain molecules or 
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pathogens. Disruption of the intestinal mucous layer or suppression of mucous production has 
shown to lead to hyperpermeability.  
Mucus consists of large, highly glycosylated proteins called mucins (60). Mucins are 
concentrated into mucin domains which are built on a protein core. All mucins have domains 
which give them specific properties. Transmembrane mucins have a domain that allow them 
to attach to the epithelial cell membrane and acts as a diffusion barrier in the GIT and gel-
forming mucins form mucus that protects and lubricates the GIT.  
Epithelial layer 
The epithelial layer (Figure 3) is a single layer of epithelial cells that line the gut lumen (61). 
Intestinal epithelial cells (IEC) play an important role in the absorption of nutrients and certain 
specialized IECs contribute towards immune defence and secrete hormones. These include 
enteroendocrine cells which release hormones involved in the regulation of digestion and 
goblet cells which produce mucins that play an important role in the non-specific immune 
response. 
The epithelium mediates selective permeability by transcellular and paracellular pathways 
(Figure 4) (61). Lipophilic and small hydrophilic molecules can pass the barrier transcellularly, 
while larger hydrophilic molecules pass the barrier paracellularly. During transcellular 
permeability, solutes are transported through the epithelial cells. This is regulated by selective 
transporters for amino acids, short chain fatty acids, electrolytes and sugars. During 
paracellular permeability, solutes are transported in spaces between epithelial cells. This is 
regulated by intercellular complexes present at the apical-lateral membrane junction. Amino 
acids and vitamins are transferred by means of active transport. The epithelium consists of a 
monolayer of IECs that are connected by desmosomes, tight junctions and adherens junctions. 
Tight junctions and adherens junctions use transcellular proteins to connect to the actin 
cytoskeleton. The cytoskeleton is crucial for paracellular transport.  
Spaces between epithelial cells are sealed by tight junctions (TJs), desmosomes and adherent 
junction (AJ) proteins (Figure 4) (61). The junction proteins are distributed across the 
gastrointestinal membrane and the number of proteins varies between the small intestine, large 
intestine, and between villi and crypts. The desmosomes and adherent junctions link the cells 
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together and the tight junctions control water and ion permeability and the absorption of 
proteins and bacterial antigens. 
Figure 4 Transcellular and paracellular transport and epithelial junctional complexes. Adapted 
from (60). 
Tight junctions consist of transmembrane proteins such as claudin, tricullulin and occludin that 
connect to the cytoskeleton of adjacent cells, connecting the cells together (62). This forms a 
barrier to paracellular diffusion of solutes and fluids. Desmosomes are connected to keratin 
filaments and adherens also attach to the cytoskeleton intracellularly by means of transcellular 
proteins (61). The cytoskeleton is a structure of protein filaments that expands through the 
cytosol of eukaryotic cells and makes contact points on the outer surface of the cell by means 
of junction proteins (59, 62). The cytoskeleton is essential for the paracellular pathway and for 
maintaining structure and functionality. It is thus a crucial structure for intestinal barrier 
function. 
Endothelium layer 
Endothelial cells (ECs) line the interior surface of blood vessels and lymphatic vessels and 
forms the endothelium (63). The endothelium is extremely important as it forms a selective 
barrier for the movement of molecules between blood and tissue. Endothelial cells are 
connected to each other by tight junctions, adherens junctions and gap junctions. Other cell 
types such as fibroblasts and pericytes contribute towards the maintenance of the endothelium 
where they form a vascular unit (64). 
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Spadoni et al. (64) hypothesized the existence of an additional barrier in the gastrointestinal 
tract, known as the gut-vascular barrier that restricts the size of molecules that can pass through. 
To evaluate the presence of this barrier they injected mice with different molecular sizes of 
fluorescein isothiocyanate (FITC)-dextran and examined the intestine for any dye leakage.  
They observed that a molecule of 4 kD had the ability to move through the endothelial barrier, 
whereas a molecule of 70 kD, could not.  
The endothelial barrier plays an important role in intestinal barrier function (59). In a study 
done by Sun et al. (65) different detergents were administered to rats to evaluate the response 
of the intestinal barrier. Endothelial and epithelial barrier integrity was examined for leakage. 
They showed that an increase in epithelial barrier dysfunction is directly proportional to 
detergent dosage. Higher doses induced an increase in endothelial barrier permeability.  
In vitro studies using cultured endothelial cells have shown that endothelial adhesion molecules 
and the production of cytokines can be expressed when the cells are exposed to bacterial 
endotoxin (LPS) or pro-inflammatory cytokines (65). During inflammation, an increase in 
cytokine levels and growth factors in the blood cause ECs to undergo remarkable changes, 
resulting in injury to the intestinal barrier. (66). 
The effect of the gut microbiota on the GBB 
As mentioned above, numerous factors can influence the integrity and structure of the GBB 
(58). Many studies have demonstrated the impact of the gut microbiota on the function of the 
GBB. Pathogens and probiotics can modify the function of tight junctions directly or by 
inducing an immune response (58). This leads to the increased permeability of the GBB, 
making it easier for lipopolysaccharide (LPS) to penetrate the barrier. The LPS molecule is 
present in the outer membrane of Gram-negative bacteria and is one of the strongest stimuli of 
immune response. This leads to a cycle causing further permeability. The intestinal microbiota 
of healthy individuals cannot access the liver and can only reach the spleen if the mesenteric 
lymph nodes (MLNs) are excised (64). Therefore, the microbiota is excluded from the 
bloodstream since the MLNs create a barrier, preventing the systemic circulation of the 
microbiota. However, if the GBB becomes damaged and starts to leak, microbes may cross this 
barrier and enter the blood stream, resulting in bacteraemia. Additionally, microbial pathogens 
have evolved to adhere, invade and disrupt the GBB (67). Certain pathogens can disrupt 
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intracellular junctions by interacting with cell receptors. Listeria monocytogenes is an 
opportunistic pathogen that can cross the intestinal barrier. 
Listeria monocytogenes 
Clinical Features 
Listeriosis has been recognised as a food-borne infection, mainly caused by the pathogenic 
Gram-positive bacterium, Listeria monocytogenes (68). Listeriosis primarily occurs in new-
borns, the elderly and immune-compromised individuals, especially AIDS patients. The risk of 
contracting listeriosis is 300 to 1000 times higher for AIDS patients.  
Despite the low incidence rate of this disease, it has a high mortality rate, ranging between 15% 
and 30% among patients despite early antibiotic treatment (69, 70). This makes                                
L. monocytogenes one of the most deadly food-borne pathogens in the world (71). The foods 
most often implicated include dairy products, sausages, fish and ready-to-eat dishes that are 
consumed without cooking (69).  Listeria monocytogenes has the ability to tolerate acidic 
conditions, high salt concentrations and low temperatures, making it a serious threat for the 
food processing industry (69).   
Pathophysiology 
Listeria monocytogenes infection can occur in two basic forms: perinatal listeriosis and 
listeriosis in adult patients (69). Perinatal listeriosis occurs when L. monocytogenes invades the 
foetus via the placenta leading to intra-amniotic infection, also known as chorioamnionitis (69). 
This infection usually results in abortion, or the birth of a baby with granulomatosis 
infantiseptica, a clinical syndrome characterized by the presence of micro-abscesses spread 
over the body. Listerial infection in adults commonly leads to listerial meningitis, mainly 
affecting the central nervous system (CNS). Another recurrent form of listeriosis in adults is 
septicaemia or bacteraemia. Infection of healthy individuals also generally leads to 
gastroenteritis (71). Further there are other unusual forms of listeriosis such as arteritis, 
myocarditis, hepatitis, pneumonia, etc. Listeria has the astounding ability to cross three 
protective barriers in humans, the fetoplacental barrier, intestinal barrier and the blood-brain 
barrier (72). 
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Studies have shown a direct correlation between clinical episodes of listeriosis and 
gastrointestinal symptoms (69). Evidence suggests that gastroenteritis may be the main clinical 
indication of listeriosis and that L. monocytogenes can be seen as a possible infectious agent in 
cases of diarrheal disease in humans (69). Additionally, the fact that contaminated food is the 
major source of infection indicates that the gastrointestinal tract may be the main site of entry 
of the pathogen into the host.  
Listeria monocytogenes is a facultative intracellular microorganism (73). It has the ability to 
enter the host through the intestinal mucosa by means of direct invasion or translocation (71). 
During direct invasion, L. monocytogenes permeates enterocytes lining the epithelium of 
microvilli, consequently infecting the intestinal cells. Listeria monocytogenes can also 
translocate across the M-cells of Peyer’s patches. However, studies have shown that the latter 
mechanism is not very efficient. 
Entry and colonization of host cells 
In order for L. monocytogenes to cross the gastrointestinal tract, the pathogen needs to adhere 
to the surface of the epithelial cells (67). Many bacteria produce mucinases that enable them to 
attach to epithelial cells by hydrolysing the mucins in the mucosal barrier. However,                     
L. monocytogenes does not produce mucinases, but instead produces several surface proteins 
that can bind to a specific type of mucin. The proteins, Internalin B (InlB), Internalin C (InlC) 
and Internalin J (InlJ) are responsible for this adherence step (71). These proteins are encoded 
by inlB, inlC and inlJ genes. 
Once Listeria has attached to the epithelial cells, it crosses the intestinal barrier by invading 
enterocytes using Internalin A (InlA), encoded by the inlA gene (69, 71, 74). Internalin A binds 
to the protein, E-cadherin, present in the cell membrane of the host and induces phagocytosis 
of L. monocytogenes (71). The InlA-E-cadherin is species-specific, therefore InlA does not 
interact with mouse E-cadherin, making mice an unsuitable model for oral infection with           
L. monocytogenes. Consequently, there is a necessity for further models for human listeriosis.  
After L. monocytogenes invades the host cell (Figure 5), it is surrounded by the membrane of 
the phagocytic vacuole (71). Different phospholipases cooperate with Listeriolysin O (LLO), 
a pore-forming hemolysin, to lyse the phagosome membrane and the pathogen is released into 
the cytoplasm where it starts to replicate (75).  
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Once Listeria is released from the phagosome, ActA is expressed (71, 74). This protein initiates 
the nucleation and polymerization of g-actin and f-actin filaments of the host. The 
polymerization action leads to the expulsion of the pathogen from the cytoplasm. Sometimes 
the pathogen is propelled into the cytoplasm of a neighbouring cell and the resulting 
pseudopods are then endocytosed by these cells, promoting cell-to-cell spread. The cycle 
repeats in the newly infected cells. 
 
 
 
 
 
 
 
Figure 5 Phases in the intracellular life-cycle of L. monocytogenes. (1) Adherence and cell 
entry mediated by internalin proteins; (2) escape from phagolysosome; (3) replication in 
cytosol; (4) intracellular motility due to actin nucleation; (5) formation of bacterial protrusions 
called listeriapods; (6) engulfment of protrusions; (7) lysis of two-membrane vacuole.  Adapted 
from (71, 74, 76). 
Virulence 
Listeria monocytogenes has many genes that contribute towards its virulence. The expression 
of most of these genes is regulated by the transcriptional regulator, PrfA, present in the          
plcA-prfA operon (Phosphoinositide phospholipase) (77). PrfA is activated once Listeria enters 
the cytoplasm of the host cell and then regulates the expression of several genes. These genes 
include plcA and plcB, both responsible for the production of phosphoinositide phospholipase 
C (PI-PLC), which helps L.monocytogenes escape from the phagosome (78); hly, which 
encodes pore-forming listeriolysin O; mpl, which encodes for a metalloprotease that 
contributes towards the encoding of other genes; actA, which encodes ActA, a surface protein 
Stellenbosch University  https://scholar.sun.ac.za
25 
 
that enables actin to assemble and attach to the cell. Other virulence inducing genes that are 
not regulated by PrfA, include the aforementioned inlA and inlB genes. 
Antibiotic treatment and resistance 
Listeria monocytogenes is susceptible to most antibiotics active against Gram-positive bacteria 
(79, 80). Listeriosis is usually treated with benzylpenicillin or ampicillin combined with an 
aminoglycoside. Erythromycin, tetracycline or chloramphenicol are used as alternative 
antibiotics. 
Listeria monocytogenes seldom develops resistance against antibiotics. However, recent 
studies have shown that the rate of resistance is rising (68). Most of the mechanisms involved 
in resistance include gene acquisition such as self-transferable plasmids capable of horizontal 
gene transfer (81). In a study done by Morvan et al. (68) the prevalence of resistance was 
determined for all L. monocytogenes strains isolated from humans between 1989 and 2007.      
A panel of 23 antibiotics was tested against 4668 L. monocytogenes strains. Among these 
strains, 61 were resistant to at least one antibiotic and two isolates were reported to be multi-
drug resistant. Even though several other multi-drug resistant strains have been reported over 
the years, multi-drug resistance remains unusual in L. monocytogenes, but as with many other 
pathogens, the list of effective drugs will decrease (82). Therefore, there is a need for sustained 
surveillance of the susceptibility of L. monocytogenes to antibiotics. 
In a study done by Campion et al. (83) the effect of nisin V was determined on murine models 
that have been infected with a lux-tagged L. monocytogenes strain. Bio-imaging and liver and 
spleen evaluation revealed that nisin V was effective with respect to controlling the infection. 
Probiotics 
The early days of probiotics 
In 1908, the Russian zoologist, Elie Metchnikoff, observed that a large amount of people living 
in Bulgaria lived longer than 100 years (84). He soon realized that Bulgarians consumed large 
quantities of yogurt. He consequently isolated bacteria from yogurt and determined that they 
conferred health benefits. 
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As defined by the World Health Organization (WHO) probiotics are microorganisms which 
confer health benefits when ingested in adequate amounts (85). Lactic acid bacteria belonging 
to the genera Lactobacillus and Bifidobacterium are members of the intestinal microbiota and 
are most frequently used as probiotics due to their safety and easy handling (84).  
Probiotics have numerous health benefits for the host (86). These beneficial microbes can 
influence the composition of the mutualistic microbiota, fight against toxins or adverse 
substances which originate from food, microbes or the host, they can produce bacteriocins that 
combat pathogens and they are able to modify the host epithelial and immune system. 
The effect of probiotics on the GBB 
Numerous studies using intestinal epithelial cells and mice have demonstrated that certain 
probiotics such as Lactobacillus rhamnosus GG, or the probiotic mix, VSL#3, interact with 
intestinal cells and maintain integrity of the GBB (86). Thus, many diseases can be prevented 
or treated by selecting the appropriate probiotic composition that can strengthen the GBB. 
Studies have shown that several Lactobacillus spp. induce gene-regulation pathways that lead 
to upregulation of IL-1β, resulting in the transcription of genes involved in B-cell maturation 
and lymphogenesis, which contributes towards enhanced barrier stability and function. Strains 
of Bifidobacterium, Lactobacillus and Streptococcus thermophilus supressed the expression of 
pro-inflammatory cytokines IL-6 and IL-7 and stimulated the expression of tight junction 
proteins, leading to enhanced barrier stability. Probiotics can protect the host through various 
mechanisms, which will be discussed below. 
Competitive exclusion of pathogens 
One major attribute of probiotics is their ability to bind to intestinal epithelial cells and prevent 
adhesion of pathogenic strains (86). Many probiotic strains, especially LAB have a variety of 
surface determinants that promote mucus adhesion. Once probiotic strains have adhered to 
intestinal epithelial cells they prevent colonization by pathogenic bacteria by blocking adhesion 
sites.  
Probiotics may also competitively exclude pathogens by exhausting the available nutrients and 
leaving fewer nutrients for survival of pathogenic bacteria (86, 87). When health-promoting 
bacteria thrive in the GIT, they produce organic acids and fatty acids as the main products of 
their fermentative metabolism. This lowers the pH of the GIT, preventing many pathogens such 
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as Salmonella and E. coli from growing. Therefore, probiotic strains can change the physical 
environment of the GIT so that pathogens are unable to colonize and survive inside the host.  
The effect of probiotics on the immune system 
Probiotics can protect the host from pathogens by stimulating the immune system (86, 88). 
Substances produced by LAB exert immunomodulatory activity by regulating the expression 
of toll-like receptors (TLRs), inhibiting inflammatory responses, activating the proliferation of 
lymphocytes and the production of antibodies, especially secretory IgA and activating dendritic 
cells (DCs) and natural killer (NK) cells (89). Bifidobacterium and Lactobacillus can 
effectively prevent the development of gastric mucosal lesions, alleviate allergies and provide 
defence against many pathogenic infections by enhancing innate and adaptive immunity.  
Antimicrobial substances produced by probiotics 
Most probiotic strains have the ability to produce antibacterial substances such as organic acids, 
hydrogen peroxide and bacteriocins (86). These substances inhibit the growth of pathogens by 
working individually or in combination. As mentioned previously, probiotics can be considered 
to be a delivery mechanism for bacteriocins. Most probiotic bacteria can produce bacteriocins 
in vitro. However, recent studies have shown that strains can also produce bacteriocins in vivo 
(84). A study done by Corr et al. (90) demonstrated the therapeutic effect of bacteriocin 
ABP118, produced by Lactobacillus salivarius UCC118 in mice infected with                                  
L. monocytogenes. Another study has shown that the bacteriocin, mutacin B-Ny266, produced 
by Streptococcus mutans, is able to inhibit multi-resistant pathogens in a mouse model (91). 
These AMPs produced by probiotic bacterial strains contribute towards host protection by 
acting as: (i) colonizing peptides, allowing the probiotic strain to compete with host microbiota; 
(ii) killer peptides, which eliminate pathogens or (iii) signal peptides, resulting in the 
recruitment of other bacteria in the immune system or GIT (43). 
Probiotics are potential candidates for delivery and production of therapeutic agents, such as 
bacteriocins, within the GIT. For this study, focus will be on two probiotic strains, L. plantarum 
423 and E. mundtii ST4SA and the bacteriocins that are naturally produced by these strains, 
plantaricin 423 and bacST4SA. 
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Lactobacillus plantarum 423 and Enterococcus mundtii ST4SA 
As mentioned previously L. plantarum 423 and E. mundtii ST4SA are combined to form the 
well-known probiotic, Entiro™. Both L. plantarum 423 and E. mundtii ST4SA, contain genes 
that encode adhesion proteins which help them bind to the mucus and epithelial layers of the 
gastrointestinal tract (23). Adhesion prevents pathogens from binding and causing disease. One 
of the most unique properties of Entiro™ is its ability to produce powerful antimicrobial 
peptides, plantaricin 423 and bacST4SA (described above) that kill gastrointestinal pathogens. 
These bacteriocins have the potential to be developed as alternatives to antibiotics. 
Drug development 
Before a new drug can be developed, one should determine which requirements are necessary 
for the process. The mission of the Food and Drug Administrations (FDA) centre for drug 
evaluation and research (CDER) is to ensure that drugs marketed are safe and effective. 
Thousands of newly discovered drugs are potential candidates for development as a medical 
treatment (85). However, after pharmacological studies are done, only a small number are 
suitable for further testing.  
From discovering a potential drug to actually having a commercial medication requires a long, 
expensive and complicated process (92). The development of a commercial drug can take as 
long as 13 years (10). On average, only 1 in 5000 candidate compounds will reach the market. 
Most failures during early development are due to toxicity, and the majority of failures during 
late-stage development are due to a lack of efficacy. Due to these complications, only about 20 
new drugs are approved each year. The first step in the drug development process entails the 
discovery of a potential drug (85) (Figure 6). Once a potential compound has been identified, 
experiments are conducted to gather information on the absorption, distribution, metabolism 
and excretion of the drug. This may be referred to as the ADME-process (84, 92). Additionally, 
the interaction with other drugs, potential benefits, mechanism of action, best route of 
administration, toxicity, effectiveness and difference in efficacy between different groups of 
people are also determined during the development process. The second step in the drug 
development process is preclinical research. Before a new drug can be tested in humans, 
experiments must be conducted in vitro and in vivo to determine the dosing and toxicity levels. 
After preclinical testing, results are examined and researchers decide whether human tests 
should commence. During clinical research, trials are conducted in different phases to examine 
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the toxicity, dose and side effects of the drug when administered to humans. The results are 
examined and if the drug meets the criteria, the clinical research is approved. Once the drug 
development company has evidence from the early tests, preclinical and clinical research that 
the drug is both safe and effective, the company can apply to market the drug. The data is 
submitted to the FDA review team and a decision is made. If the drug is approved, it will be 
marketed and sold as prescription or over-the-counter medication. The last step of the drug 
development process involves post-market safety monitoring by the FDA. Any problems 
associated with the safety and effectiveness of the drug after it has been approved, will be 
monitored and any issues will be reported. The drug might even be retracted from the market.  
 
Figure 6 Steps in the drug development process (84). 
At the start of the 20th century, drugs were not developed based on research regarding the safety 
of drugs (94). Instead, the FDA focused on the purity and physical and chemical characteristics 
of drugs. Drugs were mainly developed from plant extracts. Substances such as morphine and 
cocaine, which are subjected to restrictions today, were freely sold. However, with recent 
advances in technology, the pharmaceutical industry has made exceptional progress regarding 
the development of new medications (94).  
Various assays using cell cultures of human or animal origin are now available (95). The two-
dimensional (2-D) cell culture is an important tool for drug discovery. Through these assays it 
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is possible to observe the toxicity and efficacy of substances by accessing cell death statistics, 
immune response, protein expression, etc.  
Using tissue culture as tool for studying pathophysiology and pharmacology 
Human colonic adenocarcinoma (Caco-2) cells 
The popularity of using epithelial cell lines in drug development studies has increased 
drastically (96). Caco-2 cells are the most commonly used cell line for drug transport studies 
since it is similar to the gastrointestinal epithelium (96). These cells originate from human 
colonic adenocarcinoma. They are favourable since they are of human origin and the oral route 
is the most important route of drug administration and the clinical success of a drug may depend 
on the degree at which it is absorbed in the GIT. These cells can therefore be used to simulate 
the GIT during drug development to access drug cytotoxicity, permeability and effectiveness. 
Furthermore, Caco-2 cells have also been used to study epithelial barrier function, 
gastrointestinal pathogens, infection and disease (97). 
Drug transport studies are easy to perform on permeable supports such as transmigration insets. 
To mimic the gastrointestinal epithelium, Caco-2 cells are cultured on these transmigration 
inserts until they reach confluency and differentiate (98) (Figure 7). Transmigration inserts are 
usually made from polyester, polycarbonate or polyethylene terephthalate. The latter is claimed 
to have non-specific protein-binding properties. The inserts can be transparent or translucent. 
Transparent inserts are preferred during microscopy studies.  
These Caco-2 monolayers are reliable for studies on the absorption of drugs after oral intake in 
humans (96, 97). Numerous studies have compared absorption data in humans with Caco-2 
permeability and have found high correlation, especially if compounds are transported by 
means of the paracellular pathway. Valuable results and new information can be obtained 
through these simple in vitro models. Most of the recently available information regarding drug 
transport mechanisms has been acquired from epithelial cell monolayers.  
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Figure 7 The differentiation of Caco-2 cells on transmigration inserts. The cells are seeded 
onto transmigration inserts (A). After the cells reach confluence (B), they start to differentiate 
spontaneously. The cells are fully differentiated after an incubation period of around 25 days 
(C). Adapted from (98). 
Human umbilical vein endothelial cells (HUVECs) 
The vascular endothelium serves a variety of important functions. Endothelial cell monolayers 
have frequently been used to determine the effect of certain pathophysiological stimuli or 
stresses that accompany gastrointestinal tract diseases or disorders (99). 
Although most microvascular studies are done on in vivo murine models, rodents are known to 
have many differences to human with respect to vascular biology (100). Recent advances in 
technology have allowed researchers to harvest endothelial cells from several organ systems of 
different species, including humans (63, 99). The most common method used for isolating 
endothelial cells is to remove the cells from large blood vessels using specific enzymes. Human 
umbilical vein endothelial cells (HUVECs) have been enzymatically removed from human 
umbilical veins and are most often used for in vitro inflammation studies.   
Endothelial cell monolayers have been used to study microvascular responses associated with 
certain pathogenic infections associated with the GIT, since the endothelium forms an 
important layer in the GBB (99). Pathogens or toxic molecules must cross the vascular 
endothelium to enter the blood stream to invade the host. In contrast, antimicrobials such as 
antibiotics and bacteriocins, need to cross this barrier to have a beneficial effect on the host 
during treatment of a disease or infection.  
A B C 
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With reference to the above, we can conclude that it is critical to assess the interaction of drugs 
with intestinal epithelial cells and vascular endothelial cells to evaluate their selective toxicity 
before they can be considered for delivery to infectious sites. 
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ABSTRACT The antibiotic resistance crisis has resulted in an urgent need for the 
development of new antimicrobial compounds that can be used in clinical settings.  
Bacteriocins have many properties which suggests they are viable alternatives to antibiotics. 
However, little research has been done regarding the pharmacodynamics and in situ delivery 
of bacteriocins. Migration of the lantibiotic, nisin A and class IIa bacteriocins, plantaricin 423 
and bacST4SA across vascular endothelial and gastrointestinal epithelial cells was studied 
using in vitro simulations. Monolayers of human umbilical vein endothelial cells (HUVECs) 
and human colonic adenocarcinoma (Caco-2) cells were seeded onto transmigration inserts 
placed in a 24-well tissue culture plate with growth medium and exposed to fluorescently 
labelled nisin A, plantaricin 423 and bacST4SA. All three peptides diffused across HUVECs 
and Caco2 cells. A small percentage of the peptides (21% nisin A, 11% plantaricin 423 and 
12% bacST4SA) remained attached to Caco-2 cells. Only 6% nisin A and 3% bacST4SA 
attached to the HUVECs, while plantaricin 423 did not attach. The viability of both cell types 
remained unchanged when exposed to 50 µM nisin A, 50 µM plantaricin 423 and 50 µM 
bacST4SA, respectively, as determined with XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulphenyl)-
2H-Tetrazolium-5-Carboxanilide) and neutral red assays, whereas a slight decrease in cell 
viability was observed when the cell lines were treated with 100 µM peptide. Furthermore, 
nisin A, a FDA food preservative, displayed significantly higher levels of cytotoxicity 
compared to plantaricin 423 and bacST4SA in both cell lines (P<0.05). The three peptides 
retained 60% of their antimicrobial activity when individually exposed to 80% human plasma 
for 24 h at a concentration of 25 µM, but with increasing concentrations, this loss of 
antimicrobial activity became less pronounced (68% and 79% activity retained at 50 µM and 
100 µM respectively). The stability of the peptides in the presence of human blood plasma 
increased as exposure time increased from 24 h to 48 h to 72 h, as expected. This is the first 
report of nisin A, plantaricin 423 and bacST4SA migrating across simulated gastrointestinal- 
and vascular barriers. In vivo studies are required to confirm these findings and determine the 
effect these peptides may have in the treatment of systemic infections.   
Keywords Caco-2 cells, HUVECs, XTT assay, neutral red assay, LDH release assay, human 
plasma, cytotoxicity 
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INTRODUCTION  
Several studies have shown the tremendous health benefits of probiotics, defined by the 
FAO/WHO as living microorganisms which convey health benefits on the host when 
administered in adequate amounts (1, 2). Lactic acid bacteria belonging to the genera 
Lactobacillus and Bifidobacterium are most frequently used as probiotics (3). Many of these 
strains produce antimicrobial compounds, including bacteriocins, that may assist in the control 
of gastrointestinal infections (4). Studies using human intestinal epithelial cells and mice have 
suggested that probiotics may also play a role in maintaining the integrity of the gut-blood 
barrier (GBB) (5). However, little is known about the migration of bacteriocins across 
gastrointestinal epithelial and vascular endothelial cell barriers.  
The probiotic properties of Lactobacillus plantarum 423 and Enterococcus mundtii ST4SA 
have been well studied (6–13). Lactobacillus plantarum 423 adheres to the small intestine and 
lower part of the gastrointestinal tract (GIT) and E. mundtii ST4SA to the lower part of the GIT 
(8). This prevents gastrointestinal pathogens such as L. monocytogenes from attaching to the 
GIT (6, 13). Van Zyl and co-workers (9) used in vivo bioluminescence to show that 
colonization of mice with L. plantarum 423 and E. mundtii ST4SA prevents systemic L. 
monocytogenes EGDe infection. These bacteria can also adhere to Caco-2 cells under 
conditions simulating the gastrointestinal tract as determined by Botes et al. (6). However, the 
adhesion of Listeria monocytogenes ScottA to Caco-2 cells was not prevented by L. plantarum 
423 and E. mundtii ST4SA. Instead, the cell-free supernatants of these strains, containing the 
antimicrobial peptides, plantaricin 423 and bacST4SA, prevented the invasion of L. 
monocytogenes ScottA into Caco-2 cells (6). 
Lactobacillus plantarum 423 produces plantaricin 423, a class IIa bacteriocin, which is active 
against a variety of Gram-positive bacteria, including many opportunistic pathogens such as 
Listeria monocytogenes, Enterococcus faecalis and Clostridium sporogenes (14, 15). 
Enterococcus mundtii ST4SA produces bacteriocin ST4SA (bacST4SA), which is also a class 
IIa bacteriocin (16). The peptide is active against Gram-positive pathogens such as 
Staphylococcus aureus, E. faecalis and Streptococcus pneumoniae and Gram-negative bacteria 
such as Klebsiella pneumoniae and Pseudomonas aeruginosa (12, 16). Plantaricin 423 and 
bacST4SA bind to cell membranes by means of electrostatic interactions between positively 
charged amino acids and negatively charged phospholipids in the bacterial membrane (7, 14, 
15). Pores are formed in the cytoplasmic membrane, resulting in dissipation of the proton 
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motive force and cell death. This may play an important role in the competitive exclusion of 
pathogens in the gastrointestinal tract.   
Nisin A, produced by Lactococcus lactis subsp. lactis is active against a variety of Gram-
positive bacteria, including Listeria, Staphylococcus, Bacillus and Clostridium spp. (17). Many 
studies (17, 18) have been done on nisin A making it a viable control in bacteriocin studies. It 
is commercially available as Nisaplin® which has been used as a food preservative for years 
and has GRAS (generally regarded as safe) status (17, 19, 20). This lantibiotic binds to lipid II 
in the bacterial cell wall and prevents cell wall biosynthesis and/or forms pores in the cell 
membrane, leading to depolarization of the bacterial cytoplasmic membrane and the efflux of 
cell components, all of which result in cell death (21). 
Experiments conducted on mice have shown that bacteriocins may have beneficial therapeutic 
properties in vivo. Corr et al. (22) demonstrated that the probiotic strain, Lactobacillus 
salivarius UCC118, produces a bacteriocin (Abp118) in vivo that protects mice against 
infection with L. monocytogenes EGDe. Nisin F suppressed the growth of S. aureus in the 
peritoneal cavity for at least 15 min (23). However, bioluminescence revealed the re-emergence 
of S. aureus after 44 h, suggesting that nisin F was degraded by proteolytic enzymes (23).  In 
another study, Brand and co-workers (24) showed that intraperitoneal administration is an 
optimal route for treatment with bacteriocins. An immediate decrease in infection was observed 
after nisin F was injected into mice infected with L. monocytogenes EGDe and S. aureus (24). 
Moreover, nisin F may have a stabilizing effect on the microbiota, since the bacterial 
population in the GIT of mice remained relatively unchanged after nisin F was administered 
intraperitoneally (25). In another study, nisin stimulated the activity of interleukin-6 (IL-6), 
interleukin-10 (IL-10) and tumor necrosis factor (TNF) in mice (26). However, the immune 
response triggered by nisin was too low to result in a detectable immune reaction (26). Jabés 
and colleagues (27) evaluated the in vivo efficacy of nisin NAI-107 in animal models with 
severe infection induced by methicillin-resistant S. aureus (MRSA), glycopeptide-intermediate 
S. aureus (GISA), penicillin-intermediate S. pneumoniae (PISP) or vancomycin-resistant 
Enterococci (VRE). Results demonstrated that intravenously administered NAI-107 was 
comparable or superior to traditional reference compounds used. Furthermore, NAI-107 was 
more effective when administered intravenously than subcutaneously. This suggested limited 
bioavailability by the latter route due to protein binding or degradation by proteases.  
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Bacteriocins with bactericidal properties, such as those mentioned above, may serve as an 
alternative to antibiotics and could improve the outcome of a number of bacterial infections, 
including those caused by multidrug-resistant strains (28). Bacteriocins are bactericidal at low 
(nanomolar or micromolar) concentrations and are not toxic to humans when administered at 
MIC (minimum inhibitory concentration) levels (29, 30). Furthermore, since bacteriocins are 
ribosomally encoded, genes involved in the production of the mature (active) peptide are easily 
identified and cloned into a different host, or the producer strain may be genetically engineered 
to produce an increased yield of native bacteriocin (31, 32). 
Drugs administered orally not only need to withstand harsh conditions of the GIT, but also 
need to cross the highly selective gastrointestinal epithelial and vascular endothelial cells of 
the GBB (gut-blood barrier), to enter the blood stream. Most bacteriocins are degraded by 
proteolytic enzymes in the GIT and are unstable in chemically complex environments such as 
blood because they are degraded by proteases and bind to blood cells and plasma proteins (32–
34). The proteolytic stabilities of therapeutic compounds vary among serum, plasma and fresh 
blood, because the composition of proteases differs between these blood components and 
because different proteases act at different cleavage sites (35). In blood coagulation, serine 
proteases are mostly involved, thus cleaving C-terminal lysine or arginine. These proteases 
also degrade peptides that contain basic residues for binding to targets via ion interactions.  
Bacteriocins can to be encapsulated in protective nanoparticles or macrophages to overcome 
in vivo degradation (36, 37). Another option is to use probiotic bacteria (encapsulated if 
needed) as delivery vehicles to constantly secrete bacteriocins in the GIT (38). With recent 
developments in nanotechnology (37, 39, 40), macrophage modification (36) and the latest 
knowledge gained on the expression of genes coding for bacteriocin production and secretion 
(14, 31, 41–43), target-specific delivery of bacteriocins could soon become a reality. However, 
little research has been done on the pharmacodynamics of bacteriocins (44, 45) and we do not 
know if these peptides are able to migrate across gut epithelial or vascular endothelial barriers.  
Mechanisms associated with barrier selectivity are not fully understood. Molecular size and 
physiochemical properties of substances may play a crucial role (46). The hydrophobicity of 
bacteriocins suggests they may interact with epithelial cells in the GIT, but this could also lead 
to undesired cytotoxicity. Moreover, because of the small size of bacteriocins, they may have 
the ability to migrate across barriers paracellularly. Human colonic adenocarcinoma (Caco-2) 
cells are most commonly used in drug transport studies since the oral route is the most 
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important drug administration route and the degree of intestinal absorption may determine the 
clinical success or failure of a therapeutic agent (47). Human umbilical vein endothelial cells 
(HUVECs) are enzymatically removed from human umbilical veins and are commonly used in 
in vitro studies, especially in inflammation studies.  
In this study, HUVEC and Caco-2 cell monolayers were used to simulate the epithelial and 
vascular endothelial barriers in the GBB to study the migration of nisin A, plantaricin 423 and 
bacST4SA across these barriers. We also report on the cytotoxic effect these peptides have on 
the two cell lines. Furthermore, bacteriocin stability was monitored in human plasma.  
MATERIALS 
Bacterial growth media, trifluoroacetic acid (TFA), XAD-16 beads, ammonium sulphate, 
acetonitrile and isopropanol were from Merck (Darmstadt, Germany). SepPak C18 columns 
were from Waters (Massachusetts, USA). Nisaplin was from Danisco (Copenhagen, Denmark). 
The bicinchoninic acid (BCA) protein assay was from Pierce Biotechnology (Massachusetts, 
USA). NHS-fluorescein was from Thermo Fisher Scientific (Massachusetts, USA). Trypsin 
and trypan blue were from Whitehead Scientific (Cape Town, SA). Dulbecco’s modified 
Eagle’s medium (DMEM) was from Merck (Darmstadt, Germany) and complete endothelial 
growth medium (EGM) was from Lonza (Basel, Switzerland). 
METHODS 
Peptide production and purification 
Single colonies of L. plantarum 423 and E. mundtii ST4SA were inoculated into 10 ml MRS 
broth, incubated for 18 h at 37℃ and transferred to 2 L MRS broth. After 18 h of incubation at 
37℃, cells were harvested (11 000 x g for 20 min at 4℃). The pH of the cell-free supernatant 
was adjusted to 7.0 and heat-treated at 80℃ for 10 min to inactivate proteases and precipitate 
heat labile proteins. Bacteriocins were precipitated from the cell-free supernatants with 70% 
saturated ammonium sulphate, as described by Todorov et al. (48) and placed on an orbital 
shaker (200 rpm) at 8℃ for 48 h for precipitation to take place. The precipitate was collected 
by centrifugation (20 000 x g, 1 h) and resuspended in sterile phosphate buffered saline (PBS; 
pH 7.0). The suspension was heat treated at 80℃ for 15 min to bring peptides into solution and 
then freeze-dried. The freeze-dried peptides were dissolved in sterile PBS and added to 40 g 
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XAD-16 beads that have been pre-activated with 80% (v/v) isopropanol containing 0.1% (v/v) 
trifluoroacetic acid (TFA). After 24 h on an orbital shaker, the beads were collected and washed 
with 30% (v/v) ethanol for 15 min. Hydrophobic peptides were eluted from the beads with 70% 
(v/v) isopropanol containing 0.1% (v/v) TFA. The beads were left in suspension for 18 h on an 
orbital shaker (100 rpm) at 8℃. The peptides were separated from the beads by filtering through 
a 0.45 µM cellulose acetate filter and the isopropanol evaporated with rotary evaporation 
(RotaVapor®, Buchi). Peptides were further purified using Sep-Pak C18 reverse phase 
columns and eluted using 60% (v/v) ispopropanol containing 0.1% (v/v) TFA. Isopropanol was 
removed with rotary evaporation, active fractions were freeze-dried and antimicrobial activity 
was tested by using the agar well diffusion assay (49). Commercially available Nisaplin® was 
dissolved in 25% acetonitrile (v/v) containing 0.1% (v/v) TFA and centrifuged to remove 
undissolved particles. The supernatant was loaded onto a Sep-Pak C18 reverse phase column 
and eluted with 40% (v/v) acetonitrile containing 0.1% (v/v) TFA. Active fractions were 
freeze-dried and tested for activity as mentioned previously (49). 
Peptides were further purified by fast protein liquid chromatography (FPLC) (ÄKTA purifier; 
GE Healthcare Life Sciences, Mississauga, Canada). Samples were dissolved in 10% (v/v) 
acetonitrile containing 0.1% (v/v) TFA and added to a HiScale Source 15 RRC column (HIVD 
SepSci, South Africa). Plantaricin 423 and bactST4SA were eluted with an increasing gradient 
of 10% (v/v) to 55% (v/v) acetonitrile containing 0.1% (v/v) TFA. Peaks were detected 
measuring absorbance at 254 nm. Fractions from each peak were collected and tested for 
activity as described elsewhere (49). Active samples were freeze-dried, dissolved in 10% (v/v) 
acetonitrile and loaded onto a Discovery BIO Wide Pore C18 HPLC (high performance liquid 
chromatography) column (10 µm, 250 x 10 mm; Sigma-Aldrich, Missouri, US). Plantaricin 
423 and bacST4SA were eluted in an acetonitrile gradient of 25% (v/v) to 60% (v/v) 
acetonitrile containing 0.1% (v/v) TFA and nisin in an increasing gradient of 10% (v/v) to 60% 
(v/v) acetonitrile containing 0.1% (v/v) TFA. Peaks were collected and tested for activity as 
described elsewhere. Active peptides were freeze-dried, re-suspended in sterile ultrapure water 
containing 0.1% (v/v) TFA and analysed by liquid chromatography-mass spectrometry (LC-
MS; Central Analytical Facility, Stellenbosch, South Africa). A Waters Quadrupole Time-of-
Flight Synapt G2 (Waters Corporation, Milford, USA) was used for the LC-MS. 
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Determination of minimum inhibitory concentration (MIC) 
The bicinchoninic albumin assay (BCA) was used to determine the concentration of the 
peptides. The MIC of the peptides against Listeria monocytogenes EGDe was determined using 
a microtiter plate. Briefly, an overnight culture of the microorganism was inoculated into L. 
monocytogenes EGDe enrichment broth (LEB) and incubated overnight at 37℃. The culture 
was inoculated into fresh LEB and incubated until an OD600 of 0.1 was reached. A series of 
peptide concentrations was prepared and 50 µl of each added per well, followed by the addition 
of 150 µl culture. The controls were ultrapure water containing 0.1% (v/v) TFA with 150 µl 
culture or media. Microtiter plates were incubated at 37 ℃ and OD600 readings were taken at 
T0, T5 and T18 (hours). The MIC was determined as the lowest peptide concentration required 
to inhibit the growth of L. monocytogenes EGDe after 18 h.  
Plasma stability assay 
Human blood was collected in anticoagulant tubes (Greiner Bio-One, Kremsmünster, Austria), 
centrifuged at 500 x g (10 min, 25 ℃) and the plasma collected. Different plasma 
concentrations (0%, 40% and 80%, v/v) were prepared by diluting with sterile ultrapure water 
containing 0.1% (v/v) TFA, and aliquoted into sterile microcentrifuge tubes. Nisin A, 
plantaricin 423 and bacST4SA, each suspended in sterile ultrapure water containing 0.1% (v/v) 
TFA, were added to the plasma to final concentrations of 25 µM, 50 µM and 100 µM, 
respectively. Sterile ultrapure water containing 0.1% (v/v) TFA was used as control. Incubation 
was at 37℃ for 3 days and bacteriocin activity was tested by agar diffusion, using L. 
monocytogenes EGDe as target (49). Listeria monocytogenes EGDe was used as target 
organism. Digital images of the plates were taken after incubation and activity quantified by 
measuring the size of the zones using ImageJ software (version 1.5; https://imagej.nih.gov/ij/).  
Cell culture 
Human colonic adenocarcinoma (Caco-2) cells (South African Medical Research Council, 
Cape Town, SA) were used between passages 50-60.) and were grown in DMEM. Human 
umbilical vein endothelial cells (HUVECs; Lonza, Basel, Switzerland) were used between 
passages 5-15 and grown in complete EGM. Both cell lines were cultured at 37℃ in a 
humidified atmosphere in the presence of 5% CO2. Cell cultures were routinely sub-cultured 
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before reaching confluence. Cells were treated with trypsin and counted using a 
haemocytometer.  
For viability and cytotoxicity studies, cells were seeded in 96-well flat-bottom culture plates 
(1 × 104 cells/well). To determine migration of nisin A, plantaricin 423 and bacST4SA across 
the gastrointestinal epithelial and vascular endothelial barriers, HUVECs and Caco-2 cells were 
grown on an 8 µM pore size tissue culture insert (Qiagen, Hilden, Germany). All cell culture 
experiments were done in triplicate and have been repeated more than three times.  
Viability and cytotoxicity assays 
XTT Assay 
The colorimetric XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulphenyl)-2H-Tetrazolium-5-
Carboxanilide) assay (Merck, USA) was used to assess cell viability based on metabolic 
activity. Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring of XTT, 
resulting in the formation of an orange formazan product which is measured 
spectrophotometrically. The HUVECs or Caco-2 cells were grown in 100 µl of culture medium 
for 24 h at 37℃. Each of the bacteriocins (nisin A, plantaricin 423 and bacST4SA) were added 
to the culture at concentrations of 25 µM, 50 µM and 100 µM. Sterile ultrapure water 
containing 0.1% (v/v) TFA was used as control. After 24 h of incubation at 37℃, the reaction 
mixture containing PMS (N-methyl-dibenzopyrazine-methylsulfate/phenazine methosulphate) 
and XTT solution, was added to each well and incubated for 4 h at 37℃. Absorbance readings 
were recorded at 450 nm, using a microtiter plate reader (EZ Read 400, Biochrom, Cambridge, 
UK). The percentage viability was calculated as AT/AC × 100; where AT is the absorbance of 
peptide-treated cells and AC is the absorbance of control (untreated cells). 
Neutral Red Assay 
Cell viability was verified using the neutral red assay (Merck, Darmstadt, Germany). Neutral 
red dye is transported into the lysosome of viable cells. Thus, the amount of dye uptake is 
proportional to the number of viable cells. Cells were treated with different concentrations of 
the peptides as described for the XTT assay. Sterile ultrapure water containing 0.1% (v/v) TFA 
was used as control. After incubation at 37℃ for 24 h, neutral red solution was added to the 
cells (10% of the culture volume). After 4 h of incubation at 37℃, the medium was removed 
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by aspiration and the cells were rinsed with neutral red fixative. The fixative was removed, 
followed by the addition of neutral red and the cells were gently stirred for 10 min on a gyratory 
shaker. Absorbance readings were recorded at 540 nm and 690 nm, respectively, using a 
microtiter plate reader. The percentage viability was calculated as the absorbance of treated 
cells divided by the absorbance of untreated cells (AT/AC × 100). 
LDH Release Assay 
HUVECs and Caco-2 cells were exposed to three different concentrations (25 µM, 50 µM and 
100 µM) nisin A, plantaricin 423 and bacST4SA and the presence of extracellular LDH 
(Lactate Dehydrogenase) determined using the LDH release assay kit (Merck, Darmstadt, 
Germany). Sterile ultrapure water containing 0.1% (v/v) TFA was used as negative control 
(referred to as spontaneous LDH activity) and lysis buffer (10X) was used as positive control 
(referred to as maximum LDH activity). After incubating the cultures in the presence of the 
peptides for 24 h at 37℃, culture supernatants were pipetted into a 96-well plate. Reaction 
mixture was added to the supernatants and plates were incubated at 25℃ for 30 min. 
Absorbance was measured at 490 nm and 680 nm, respectively. The percentage cytotoxicity 
was calculated as follows: 
% Cytotoxicity =  (Compound−treated LDH activity)−(Spontaneous LDH activity)
Maximum LDH activity−Spontaneous LDH activity  × 100  
 
Labelling peptides with NHS-fluorescein 
Purified stock solutions of nisin A, plantaricin 423 and bacST4SA were prepared by dissolving 
the peptides in sterile ultrapure water containing 0.1% (v/v) TFA. Concentrations were 
determined using the BCA assay, as described elsewhere. Immediately before conjugating 
fluorescein to the peptides, a stock solution of NHS-fluorescein was prepared by dissolving 1 
mg of reagent in 100 µl DMF. The amount of NHS-fluorescein to be added to each peptide was 
calculated using the following equations: 
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ml peptide × mg peptideml peptide  × mmol peptidemg peptide  × 15 mmol NHSmmol peptide  = mmol NHS  
 
mmol NHS × 473.4 mg (molecular weight of NHS)mmol NHS  × 100 µl Solvent (DMF)1 mg  = µl NHS 
 
The calculated concentration of NHS-fluorescein was added to the peptides and incubated in 
the dark on ice for 2h. Non-reacted NHS-fluorescein was removed by Sep-Pak C18 reverse 
phase column chromatography. Plantaricin 423 and bacST4SA were eluted with 60% 
isopropanol containing 0.1% (v/v) TFA and nisin A with 40% acetonitrile containing 0.1% 
(v/v) TFA. Rotary evaporation was used to remove the isopropanol. Peptides were freeze dried 
and resuspended in sterile ultrapure water containing 0.1% TFA. Concentrations of the labelled 
peptides were determined with the BCA assay and diluted to 50 µM. Labelled peptides were 
filtered through a 0.45 µm cellulose acetate membrane and spotted (20 µl) onto Listeria 
enrichment agar seeded with 1% L. monocytogenes EGDe (OD600 0.1). Plates were incubated 
overnight at 37℃ and the fluorescent peptides visualised under a UVP 3UV Ultraviolet Lamp 
(254 nm; Thermo Fisher Scientific, Massachusetts, USA). Inhibition zones were measured 
using ImageJ software and compared to those of non-labelled peptide to determine the 
percentage of activity loss due to labelling.  
Ability of bacteriocins to migrate across gastrointestinal epithelial and 
vascular endothelial cells  
HUVECs and Caco-2 cells were seeded onto transmigration inserts (Whitehead Scientific, 
Cape Town, SA), as shown in Fig. 1, at a cell density of 1× 105 cells/insert (200 μl). Inserts 
were carefully placed in a 24-well tissue culture plate containing 700 μl cell growth media. 
Cells were incubated at 37℃ in a humidified atmosphere in the presence of 5% CO2, until 
confluency was reached and a monolayer formed. Fluorescently labelled peptides (nisin A, 
plantaricin 423 and bacST4SA) were added, respectively, to the apical side of the inserts at a 
concentration of 50 μM. Transmigration inserts containing no monolayer, was used to 
determine the total fluorescence. Samples were incubated for 3 h while absorbance was 
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measured at 490 nm every 30-min using a microplate reader. Before each reading, inserts were 
placed in new microplates containing fresh media. The amount of migrated peptide was 
calculated as a percentage of total fluorescence in wells (without monolayer): 
 
% Migrated peptide = Absorbace in well (containing monolayer)
Absorbance in control well (no monolayer)  × 100 
 
After 3 h, the absorbance of the residual labelled peptide in the inserts (non-migrated peptide) 
was measured after transferring the non-migrated peptide to 24-well plates containing culture 
media to a final volume of 700 µl. The percentage residual peptide was calculated as a 
percentage of total fluorescence: 
 
% Residual (non-migrated peptide) = Absorbance in insert 
Absorbance in control well (no monolayer) × 100 
 
The cells were washed with PBS and visualised in the IVIS® 100 In Vivo Imaging System 
(Caliper Life Sciences, Hopkinton, US) to detect any labelled peptide that have attached to the 
cells or have entered the cells. The percentage of peptide that attached to, or entered the cells 
was quantified by subtracting the sum of migrated peptide and retained peptide from the total 
fluorescence. To determine the cytotoxicity of NHS-fluorescein labelled peptide, a trypan blue 
exclusion test was performed. Briefly, cells treated for 3 h with labelled nisin A, plantaricin 
423 or bacST4SA were harvested by centrifugation as described elsewhere and resuspended in 
1 ml PBS. One-part cell suspension (100 μl) was added to 100 μl trypan blue (0.4%) and 
incubated for 3 min at room temperature. The number of unstained (viable) and stained (non-
viable) cells was determined using a haemocytometer. The percentage viable cells were 
calculated by dividing the total number of viable cells per ml with the total number of cells per 
ml. The integrity of the monolayers was monitored by ensuring TEER (trans-epithelial 
electrical resistance) readings remained above 300 Ω throughout the experiment (Millicell-
ERS volt-ohm meter, Merck-Millipore, Massachusetts, United States). 
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Figure 1 Simulated gastrointestinal epithelial / vascular endothelial barrier constructed with 
HUVECs and Caco-2 cells, respectively. Transmigration inserts on which the cell lines have 
been cultured were inserted into wells of a 24-well plate.  
Statistical analysis 
All data were subjected to analysis of variance (ANOVA) followed by Dunnet’s multiple 
comparison test to detect significant differences (p < 0.05). Data was analysed using GraphPad 
Prism software (version 5.0, USA). 
RESULTS 
MIC levels of nisin A, plantaricin 423 and bacST4SA 
The MIC levels of nisin A, plantaricin 423 and bacST4SA were 8 µM, 12 µM and 10 µM, 
respectively, as determined against L. monocytogenes EGDe.  
Plasma stability of the bacteriocins 
The antimicrobial activity of nisin A, plantaricin 423 and bacST4SA, each tested at 25 µM, 50 
µM and 100 µM, decreased slightly after 3 days of incubation in the absence of plasma (Figure 
2). Of the three bacteriocins, bacST4SA was the most stable in the presence of human plasma 
at all three plasma concentrations (Figure 2). Nisin A was the least stable. At a concentration 
of 25 µM, all three bacteriocins lost a maximum of 40% of their antimicrobial activity after 24 
h in the presence of 80% plasma (Table 1). However, when 50 µM and 100 µM of the 
bacteriocins were exposed to 80% plasma, a maximum of 21% to 32% of their activity was 
lost. 
Transmigration insert 
8 µm pores 
Tissue culture media 
Well of a multi-well 
Human cell 
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Figure 2 Effect of human blood plasma on the antimicrobial activity of nisin A, plantaricin 
423 and bacST4SA over three days. Changes in the antimicrobial activity against L. 
monocytogenes EGDe were observed by spotting the peptides on agar plates and measuring 
the inhibition zones. A: 25 µM, 50 µM and 100 µM nisin A; B: 25 µM, 50 µM and 100 µM 
plantaricin 423; C: 25 µM, 50 µM and 100 µM bacST4SA. Antimicrobial activity of the 
peptides in the presence of 0% plasma (●), 40% plasma (●) and 80% plasma (●) are represented 
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as a percentage of the initial activity (100% at day 0). Curves without common letters (a-c) 
differ significantly (p < 0.05). 
Table 1 Reduction of the antimicrobial activity of nisin A, plantaricin 423 and bacteriocin 
ST4SA due to 40% plasma and 80% plasma. The percentage decrease in antimicrobial activity 
was calculated for 25 µM, 50 µM and 100 µM of the peptides.   
 
Cell viability and cytotoxicity of bacteriocins  
The cytotoxicity of nisin A, plantaricin 423 and bacST4SA, against HUVEC and Caco-2 cells 
is shown in Figures 3 to 5. Results obtained with XTT (Figure 3) and neutral red (Figure 4) 
assays showed no significant difference in percentage viability of both cell types after treatment 
with 25 µM and 50 uM of the three respective bacteriocins. However, 100 µM nisin A, 
plantaricin 423 and bacST4SA caused a slight reduction in HUVEC and Caco-2 cell viability. 
Based on the LDH release from the two cell lines, the relative cytotoxicity of the peptides was 
significantly when compared to the positive control at all three concentrations (Figure 5). 
However, the cytotoxicity levels of 100 µM nisin A, plantaricin 423 and bacST4SA were 41%, 
21% and 12% against HUVECs and 29%, 17% and 14% against Caco-2 cells. Thus, nisin A 
displayed significantly higher levels of cytotoxicity compared to plantaricin 423 and 
bacST4SA. All three peptides were more toxic to HUVECs than Caco-2 cells as the overall 
relative viability of the cells was lower after treatments during the XTT and neutral red assays 
and the relative cytotoxicity as assessed by the LDH release assay increased in a peptide dose-
dependent manner. Of the three peptides, nisin A was the most toxic to HUVECs and Caco-2 
cells and bacST4SA was best tolerated. 
 
 
 
  
Plasma 
concentration 
% Decrease in antimicrobial activity 
Nisin A Plantaricin 423 Bacteriocin ST4SA 
25 µM 50 µM 100 µM 25 µM 50 µM 100 µM 25 µM 50 µM 100 µM 
40% 79 40 26 40 30 17 39 24 16 
80% 100 93 33 60 39 29 50 36 22 
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Figure 3 The effect of antimicrobial peptides, nisin A, plantaricin 423 and bacST4SA cell 
viability using an XTT assay. A: Cell viability of CACO-2. B: Cell viability of HUVECs. Cell 
viability after treatment with 25 µM (blue), 50 µM (red) and 100 µM (grey) peptide are 
represented as a percentage of total cell viability.  Sterile ultrapure water containing 0.1% (v/v) 
TFA was used as negative control (green) and represents 100% cell viability. Significantly 
different values are indicated (p < 0.05) are indicated by *. 
 
 
 
 
 
 
 
Figure 4 The effect of antimicrobial peptides, nisin A, plantaricin 423 and bacST4SA on cell 
viability using a neutral red assay. A: Cell viability of Caco-2. B: Cell viability of HUVECs. 
Cell viability after treatment with 25 µM (blue), 50 µM (red) and 100 µM (grey) peptide are 
represented as a percentage of total cell viability.  Sterile ultrapure water containing 0.1% (v/v) 
TFA was used as negative control (green) and represents 100% cell viability. Significantly 
different values are indicated (p < 0.05) are indicated by *. 
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Figure 5 The effect of antimicrobial peptides, nisin A, plantaricin 423 and bacST4SA on 
plasma membrane integrity using an LDH release assay. A: Cytotoxicity towards Caco-2. B: 
Cytotoxicity towards HUVECs. Cytotoxicity after treatment with 25 µM (blue), 50 µM (red) 
and 100 µM (grey) peptide are represented as a percentage of maximum LDH release.  Lysis 
buffer was used as positive control (green) and represents 100% cytotoxicity. Significantly 
different values are indicated (p < 0.05) are indicated by *. 
Peptide labelling 
Nisin A, plantaricin 423 and bacST4SA were successfully labelled with NHS-fluorescein, as 
shown by clear fluorescent zones on agar seeded with L. monocytogenes EGDe (Figure 6). The 
labelled peptides were, however, less active than the unlabelled peptides, as measured by a 
decrease in activity of 32% by nisin A, 24% by plantaricin 423 and 21% by bacST4SA (Figure 
7).  
 
 
 
 
 
Figure 6 Clear fluorescent zones visualized with UV light at 254 nm. NHS-fluorescein labelled 
nisin A (A), plantaricin 423 (B) and bacST4SA (C).  
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Figure 7 Inhibition zones of labelled and unlabelled nisin A, plantaricin 423 and bacST4SA 
after spotting against L. monocytogenes EGDe. 
Ability of bacteriocins to migrate across gastrointestinal epithelial and 
vascular endothelial cells  
Migration of nisin A, plantaricin 423 and bacST4SA across HUVEC and Caco-2 cells is shown 
in Figure 8. After 3 h of incubation, 75% of nisin A, 85% of plantaricin 423 and 84% of 
bacST4SA migrated across the Caco-2 cell monolayer and a total of 90% nisin A, 96% 
plantaricin 423 and 93% bacST4SA migrated across the HUVEC monolayer (Figure 8). Based 
on these results, nisin A, plantaricin 423 and bacST4SA migrated more easily through the 
endothelial layer (HUVECs) than the epithelial layer (Caco-2 cells). In the case of all three 
bacteriocins, almost full migration across the two cell types occurred within the first 90 min 
(Figure 8). A larger percentage of plantaricin 423 migrated across the cells. After 3 h of 
incubation, approximately 4% nisin A, plantaricin 423 and bacST4SA remained in the tissue 
culture inserts after being added to either the HUVEC of Caco-2 cell monolayers (Figure 9). 
In the control inserts (no monolayer), similar results were obtained (also ± 4% residual peptide). 
Low concentrations or no fluorescently labelled peptides attached to the HUVEC and Caco-2 
cells after 3 h of incubation (Figure 10). Higher levels of fluorescence were visible in cells that 
have been treated with nisin A. No fluorescence was detected in HUVECs treated with 
plantaricin 423. The percentage attached and/or entered peptide was calculated; 21% nisin A, 
11% plantaricin 423 and 12% bacST4SA remained attached to Caco-2 cells and/or entered 
them and 6% nisin A, 0% plantaricin 423 and 3% bacST4SA attached to the HUVECs. None 
of the labelled peptides were cytotoxic to any of the two cell lines, as indicated by trypan blue 
staining (data not shown).  
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Figure 8 Ability of nisin A, plantaricin 423 and bacST4SA to migrate across a simulated 
barrier of gastrointestinal epithelial and vascular endothelial cells A: Migration of peptides 
across a Caco-2 cell monolayer. B: Migration of peptides across a HUVEC monolayer. 
Migrated nisin A (blue), plantaricin 423 (red) and bacST4SA (blue) is expressed as percentage 
of total fluorescence. Curves without common letters differ significantly (p < 0.05). 
  
 
.  
 
 
 
 
Figure 9 Percentage residual peptide that remained in the insert after 3 h of incubation. Peptides 
that did not migrate across the Caco-2 cell monolayer (A) and the HUVEC monolayer (B) are 
compared to the control (no monolayer) and expressed in percentage values. No significant 
differences were recorded. 
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Figure 10 Fluorescent peptides that attached to the Caco-2 cells (A) and HUVECs (B) after 3 
h of incubation. (1) No peptide or fluorescent marker; (2) NHS-fluorescein; (3) fluorescently 
labelled nisin A; (4) fluorescently labelled plantaricin 423; (5) fluorescently labelled 
bacST4SA. 
DISCUSSION 
It is crucial to assess the stability, safety and effectiveness of antimicrobial compounds to 
determine if they can be used as alternatives to antibiotics. Nisin A, plantaricin 423 and 
bacST4SA were more stable in human plasma when added at a concentration of 100 µM 
compared to 50 µM and 25 µM. Higher concentrations resulted in higher bioavalability of 
antimicrobials (50). Thus, a smaller percentage of the total amount of peptide administered was 
degraded by proteases or bound to proteins present in the blood. In a previous study (23), 
Staphylococcus aureus Xen 36-infected mice were treated with nisin F, which is similar to 
nisin A used in this study. Nisin F was administered intraperitoneally at a concentration of 640 
AU (arbitrary units). Results indicated that nisin F suppressed the growth of S. aureus Xen 36 
in vivo only for the first 15 min. The authors hypothesized that the re-emergence of S. aureus 
was due to degradation of nisin F by proteolytic enzymes. This may explain the loss in 
antimicrobial activity recorded for nisin A, plantaricin 423 and bacST4SA after prolonged 
exposure (1-3 days) to blood plasma. However, since these bacteriocins are membrane active 
and have hydrophobic natures, they may attach to cells or other proteins, limiting their 
availability (11, 15, 17). Most antibiotics are delivered to the site of infection within 3 h (29, 
50). Thus, results from this study indicate that the peptides remain stable in blood plasma for a 
sufficient period. Protein binding, GIT conditions, food and proteases may affect the oral 
A 
B 
1 2 3 4 5 
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administration of antimicrobials. However, in vivo experiments are required to determine the 
optimal dosage as high dosages may be toxic. 
Previous studies have shown that certain AMP such as melittin, pediocin and colicin E6 have 
the ability to interact with mammalian proteins involved in metabolism, disrupt mitochondrial 
processes, cell structure and cause apoptosis (18, 51). It is therefore crucial to study the 
interaction of AMPs with mammalian cells to evaluate their potential toxicity before they can 
be considered for delivery to infectious sites. The hydrophobicity of nisin A, plantaricin 423 
and bacST4SA suggests they may interact with epithelial cells in the GIT and cause undesired 
toxicity (51). In this study, nisin A plantaricin 423 and bacST4SA did not cause a decrease in 
HUVEC or Caco-2 cell viability at concentrations up to 50 µM in the XTT and neutral red 
assays. Results from the LDH release assay indicate that nisin A, plantaricin 423 and 
bacST4SA are cytotoxic against Caco-2 cells or HUVECs at a concentration of 100 µM. 
However, nisin A, a FDA approved food preservative, displayed significantly higher levels of 
toxicity compared to plantaricin 423 and bacST4SA in both cell lines (P<0.05). This increase 
in cytotoxicity could be associated with an increased hydrophobicity, however, the mechanisms 
involved in the different toxicity levels requires further study. The overall cytotoxicity of nisin 
A, plantaricin 423 and bacST4SA was greater against HUVECs compared to Caco-2 cells. In 
a study done by Murinda et al. (18), nisin, pediocin and selected colicins showed different 
cytotoxicity levels amongst colonic cells and Vero (kidney) cells. These differences may be 
due to the eukaryotic cell type used. However, other explanations include, potential presence 
of impurities in the AMP preparations used, loss of activity after purification, different 
exposure times, solvents or media used (51). The differences in cytotoxicity levels between 
HUVECs and Caco-2 cells are likely associated with different cell lines used as the peptides 
were pure and all solvents removed. Cytotoxicity studies carried out by Maher et al. (51) 
showed that ~80 µM nisin A did not have a significant cytotoxic effect on Caco-2 cells. This 
current study expands on this report by demonstrating that the cytotoxicity of nisin A, 
plantaricin 423 and bacST4SA increased as concentrations increased. Future in vivo studies on 
animals would provide more information regarding the maximum tolerated doses as well as 
cell type-specific responses to the peptides.  
The gastrointestinal barrier is highly selective and prevents the passage of toxic compounds of 
the luminal microbiota whilst allowing the absorption of nutrients from the gut lumen (52). 
The molecular size and physiochemical properties of substances play a significant role in this 
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selectivity. Moreover, the vascular endothelial barrier may play a vital role in maintaining the 
function and structure of the intestinal barrier. Orally administered therapeutic agents need to 
maintain stability throughout the gastrointestinal tract, cross the intestinal mucous layer, the 
epithelial barrier and the vascular endothelial barrier to reach the blood stream so that they can 
be transported to the site of infection. Oral drug delivery vectors such as probiotics can be used  
to transport AMPs to infectious sites (51). The delivery of nisin A to the site of gastrointestinal 
colonic infections has been investigated and is currently under patent (53). In this study, a 
simulation of the gastrointestinal epithelial and vascular endothelial barrier was used to 
determine if bacteriocins can cross these barriers. Since bacteriocins are small they may diffuse 
across these barriers by means of the paracellular pathway. However, during passive diffusion, 
a concentration equilibrium might be expected on either side of the transmigration insert, while 
the data from this study suggests the peptides traversed it. This may be explained by the fact 
that the transmigration inserts were placed into fresh media prior to each determination, 
resulting in multiple dialysis steps. 
Results from this study correspond to this hypothesis. The AMPs, nisin A, plantaricin 423 and 
bacST4SA can migrate across a simulation of the epithelial and endothelial layers. Moreover, 
a small amount of the peptides can attach to or enter epithelial (Caco-2) cells and nisin A and 
bacST4SA can attach to or enter endothelial cells (HUVECs). This study does not determine 
whether the bacteriocins attach or enter the mammalian cells, but it may indicate antigenicity 
of the peptide simulating phagocytosis, pinocytosis or another method of intracellular 
transport. Nisin A acts by binding to lipid II in the cell membrane of bacteria. Since similar 
lipids are present in the eukaryotic cell membrane, nisin A may have the ability to bind to these 
lipids, resulting in cytotoxicity. However, further research is required to determine exactly how 
(active or passive transport) these peptides are transported across epithelial -and endothelial 
cells. 
Plantaricin 423 is most effective at migrating across these barriers but is least effective at 
attaching to the cells. In contrast, nisin A is the least effective at crossing the barriers but a 
larger amount of the peptide attached to the cells. The difference in ability of the peptides to 
attach to mammalian cells can be due to differences in hydrophobicity, amino acid 
composition, mode of action or size. The exact mechanisms involved in eukaryotic cell 
attachment requires further investigation. A small percentage of labelled peptide remained in 
the tissue culture inserts (~4%) after an incubation period of 3 h. Since this percentage can be 
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compared to residual peptide in control inserts (no monolayer) one can conclude that a small 
amount of peptide attaches to the insert. This could be due to the hydrophobicity of the insert.  
In conclusion, current data illustrated that nisin A, plantaricin 423 and bacST4SA have no 
significant cytotoxicity at effective antimicrobial doses, that the peptides remain stable in blood 
plasma at the concentrations tested, and that they have the capacity to readily migrate across 
epithelial membranes for systemic delivery in vivo. These promising results should be 
following up by in vivo studies to determine potential tissue-specific responses to these 
peptides. Advanced visualisation techniques such as microfluidic and confocal microscopy 
could shed more light on potential occurrence of cell internalisation of peptides, as well as 
membrane transport mechanisms involved. 
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GENERAL DISCUSSION AND CONCLUSIONS 
The continued success of humankind relies on the ability to treat and prevent diseases (1). 
Unfortunately, the inappropriate and unnecessary use of antibiotics has led to the development 
of antibiotic-resistant bacteria (2). Approximately 2 million people in the Unites States are 
infected with resistant bacteria each year, resulting in a minimum of 23 000 deaths annually 
(3). The burden of infectious diseases is substantial in developing countries, such as South 
Africa, due to limited access to clean water and sanitation, malnutrition, ineffective treatment 
and the HIV/AIDS -and TB epidemics (4). Thus, alternatives to antibiotics are urgently needed 
(1).  
Bacteriocins may be a viable alternative to conventional antibiotics, since they are highly 
potent against pathogens, as determined with in vitro and in vivo studies (5–7). Bacteriocins 
are generally non-toxic (8–10) and strains may be genetically modified to produce broad -and 
narrow-spectrum peptides. One of the major disadvantages of bacteriocins is their 
susceptibility to proteolytic enzymes (11). Proteases in the GIT and blood may degrade orally 
and parenterally administered bacteriocins. While some bacteriocins may be stable enough to 
reach the site of infection, in situ bacteriocin production by probiotics is a viable alternative.  
The gut microbiota promotes human health by improving nutrient uptake, excluding pathogens 
and modulating the immune system (1). Regardless of the method used in administering 
antibiotics, the gut microbiome is always affected. An altered gut microbiome leads to infection 
by intestinal pathogens and diseases such as irritable bowel syndrome, become more prevalent.  
Probiotics maintain or improve the commensal gut microbiota and prevent the colonization by 
pathogens. Once bacteriocins have been produced in the GIT by probiotics, they need to cross 
the highly selective gastrointestinal epithelial and vascular endothelial barriers to enter the 
blood stream and be transported to the site of infection (12, 13). However, little research has 
been done on the migration of bacteriocins across these barriers.  
In this study, nisin A, plantaricin 423 and bacST4SA migrated across simulations of the 
gastrointestinal epithelial and vascular endothelial barriers. Even though a small percentage of 
the peptides attached to the cells (HUVECs and Caco-2 cells), they did not cause a decrease in 
cell viability at concentrations up to 50 µM. Nisin A, a FDA food preservative showed 
significantly higher levels of cytotoxicity compared to plantaricin 423 and bacST4SA. Nisin A 
has the lowest MIC towards L. monocytogenes EGDe, which might explain the fact that it is 
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the most toxic towards HUVECs and Caco-2 cells, compared to plantaricin 423 and bacST4SA. 
Moreover, the mode of action of nisin A, a lantibiotic, is different towards plantaricin 423 and 
bacST4SA, both classII bacteriocins.  
The mammalian phospholipid cell membrane illustrates combinations of hydrophobic and 
hydrophilic interactions (14). The hydrophilic fatty acid chains of the phospholipids are 
clustered away from contact with water, maximizing hydrophobic interactions. The 
hydrophobic groups at the exterior surface of the bilayer interact with exterior hydrophobic 
molecules and thus allow the passive diffusion of these molecules across the membrane (14, 
15). In contrast, hydrophilic molecules cannot be transported by means of passive diffusion, 
but instead require interaction with transport molecules. Thus, nisin A, plantaricin 423 and 
bacST4SA most likely interact with the cells and diffuse over the cell membranes by means of 
the paracellular pathway because of their hydrophobicity and small size. Nisin A is the least 
hydrophobic of the three peptides, with only 8 hydrophobic residues (16). It is also the smallest 
of the three peptides (3354 Da). This corresponds to the migration ability of nisin A, as a lower 
concentration diffused across the cell barriers, compared to the larger plantaricin 423 and 
bacST4SA peptides. Plantaricin 423 consists of 9 hydrophobic residues (17) and bacST4SA 
has 14 (18). A higher concentration of plantaricin 423 diffused across the barriers, compared 
to bacST4SA. This may be due to the much larger size of bacST4SA (4288 Da) compared to 
plantaricin 423 (3935 Da), but the exact mechanism associated with cell attachment and 
migration requires further research. It is also crucial to assess the migration ability of 
bacteriocins in the presence of the mucus layer. The mucus layer forms a protective barrier, 
preventing the diffusion of certain pathogens and molecules (19). Studies have shown that most 
probiotic bacteria attach to the mucus layer (20–23), but it is unknown whether bacteriocins 
produced by these probiotics, attach to the layer as well. This may prevent the diffusion of 
bacteriocins into the bloodstream, but further studies are required to determine this. 
This is the first report where NHS-fluorescein labelled bacteriocins were used to determine the 
migration ability of bacteriocins across HUVEC and Caco-2 cell monolayers. This is a viable 
system that can be used in other drug transportation studies using different bacteriocins. 
Moreover, since NHS-fluorescein is not cytotoxic towards these human cell lines, it might also 
have no toxic effects on animal models, suggesting that this labelling system could potentially 
be used in in vivo experiments to track therapeutic peptides. These promising results should be 
following up by in vivo studies to determine potential tissue-specific responses to these 
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peptides. Advanced visualisation techniques such as microfluidic and confocal microscopy 
could shed more light on potential occurrence of cell internalisation of peptides, as well as 
membrane transport mechanisms involved. 
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